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Abstract
Automated quantitative neuroimaging analysis methods have been crucial in elucidating normal and
pathological brain structure and function, and in building in vivo markers of disease and its progression.
Commonly used methods can identify and precisely quantify
subtle and spatially complex imaging patterns of brain change associated with brain diseases. However, the
overarching premise of these methods is that the disease group is a homogeneous entity resulting from a
single, unifying pathophysiological process that has
a single imaging signature. This assumption ignores ample evidence for the heterogeneous nature of
neurodegenerative diseases and neuropsychiatric disorders, resulting in incomplete or misleading
descriptions. Accurate characterization of heterogeneity is important
for deepening our understanding of neurobiological processes, thus leading to improved disease diagnosis and
prognosis.
In this thesis, we leveraged machine learning techniques to develop novel tools that can analyze the
heterogeneity in both cross-sectional and longitudinal neuroimaging studies. Specifically, we developed a
semi-supervised clustering method for characterizing
heterogeneity in cross-sectional group comparison studies, where normal and patient populations are
modeled as high-dimensional point distributions, and heterogeneous disease effects are captured by
estimating multiple transformations that align the two distributions, while accounting for the effect of
nuisance covariates. Moreover, toward dissecting the heterogeneity in longitudinal cohorts, we proposed a
method which simultaneously fits multiple population longitudinal multivariate trajectories and clusters
subjects into subgroups. Longitudinal trajectories are modeled using spatiotemporally regularized cubic
splines, while clustering is performed by assigning subjects to the subgroup whose population trajectory best
fits their data.
The proposed tools were extensively validated using synthetic data. Importantly, they were applied to study
the heterogeneity in large clinical neuroimaging cohorts. We identified four disease subtypes with distinct
imaging signatures using data from Alzheimer’s
Disease Neuroimaging Initiative, and revealed two subgroups with different longitudinal patterns using data
from Baltimore Longitudinal Study on Aging. Critically, we were able to further characterize the subgroups in
each of the studies by performing statistical analyses
evaluating subgroup differences with additional information such as neurocognitive data. Our results
demonstrate the strength of the developed methods, and may pave the road for a broader understanding of the
complexity of brain aging and Alzheimer’s disease.
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ABSTRACT
ANALYZING HETEROGENEITY IN NEUROIMAGING WITH PROBABILISTIC
MULTIVARIATE CLUSTERING APPROACHES
Aoyan Dong
Christos Davatzikos
Automated quantitative neuroimaging analysis methods have been crucial in elucidat-
ing normal and pathological brain structure and function, and in building in vivo markers
of disease and its progression. Commonly used methods can identify and precisely quan-
tify subtle and spatially complex imaging patterns of brain change associated with brain
diseases. However, the overarching premise of these methods is that the disease group is a
homogeneous entity resulting from a single, unifying pathophysiological process that has
a single imaging signature. This assumption ignores ample evidence for the heterogeneous
nature of neurodegenerative diseases and neuropsychiatric disorders, resulting in incom-
plete or misleading descriptions. Accurate characterization of heterogeneity is important
for deepening our understanding of neurobiological processes, thus leading to improved
disease diagnosis and prognosis.
In this thesis, we leveraged machine learning techniques to develop novel tools that
can analyze the heterogeneity in both cross-sectional and longitudinal neuroimaging stud-
ies. Specifically, we developed a semi-supervised clustering method for characterizing
heterogeneity in cross-sectional group comparison studies, where normal and patient pop-
ulations are modeled as high-dimensional point distributions, and heterogeneous disease
effects are captured by estimating multiple transformations that align the two distribu-
tions, while accounting for the effect of nuisance covariates. Moreover, toward dissecting
v
the heterogeneity in longitudinal cohorts, we proposed a method which simultaneously
fits multiple population longitudinal multivariate trajectories and clusters subjects into
subgroups. Longitudinal trajectories are modeled using spatiotemporally regularized cu-
bic splines, while clustering is performed by assigning subjects to the subgroup whose
population trajectory best fits their data.
The proposed tools were extensively validated using synthetic data. Importantly, they
were applied to study the heterogeneity in large clinical neuroimaging cohorts. We iden-
tified four disease subtypes with distinct imaging signatures using data from Alzheimer’s
Disease Neuroimaging Initiative, and revealed two subgroups with different longitudinal
patterns using data from Baltimore Longitudinal Study on Aging. Critically, we were able
to further characterize the subgroups in each of the studies by performing statistical anal-
yses evaluating subgroup differences with additional information such as neurocognitive
data. Our results demonstrate the strength of the developed methods, and may pave the
road for a broader understanding of the complexity of brain aging and Alzheimer’s dis-
ease.
vi
Contents
Acknowledgments iii
Abstract v
Contents vi
List of Tables x
List of Figures xi
1 Introduction 1
1.1 Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Contributions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.3 Image preprocessing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.3.1 Datasets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.3.2 Feature extraction from structural scans . . . . . . . . . . . . . . . . . 9
1.4 Organization of this thesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
2 Clustering Imaging Patterns of Disease Effect via Distribution Matching 12
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
vii
2.2 Method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.2.1 Log-likelihood term . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.2.2 Model regularization . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
2.2.3 Optimization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.2.4 Clustering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.3 Experiments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.3.1 Synthetic data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.3.2 Neurodegenerative disease data . . . . . . . . . . . . . . . . . . . . . 29
2.4 Conclusion and discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3 Capturing Heterogeneity in Prodromal Alzheimer’s Disease 34
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
3.2 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
3.2.1 Subjects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
3.2.2 Cerebrospinal fluid (CSF) collection and measurement . . . . . . . . 38
3.2.3 MRI acquisition and processing . . . . . . . . . . . . . . . . . . . . . . 38
3.2.4 White matter hyperintensities (WMH) . . . . . . . . . . . . . . . . . . 39
3.2.5 Heterogeneity and voxel based morphometry analysis . . . . . . . . 39
3.2.6 Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
3.3 Experiments and results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3.3.1 Cluster demographic and genetic characteristics . . . . . . . . . . . . 41
3.3.2 Cluster membership confidence . . . . . . . . . . . . . . . . . . . . . 42
3.3.3 Cross-sectional clinical and biomarker associations . . . . . . . . . . 42
3.3.4 Group-wise VBM results . . . . . . . . . . . . . . . . . . . . . . . . . . 46
viii
3.3.5 Longitudinal changes . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.3.6 Prevalence of clusters as a function of age . . . . . . . . . . . . . . . . 50
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
4 Parsing Heterogeneous Longitudinal Trajectories 64
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
4.2 Method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
4.2.1 Loss term . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
4.2.2 Regularization term . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
4.2.3 Optimization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
4.3 Experiments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
4.3.1 Synthetic data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
4.3.2 Longitudinal aging data . . . . . . . . . . . . . . . . . . . . . . . . . . 80
4.4 Discussion and conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
5 Summary and Future Work 90
5.1 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
5.2 Future work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
A Software 96
B List of regions of interest 99
C BLSA cognitive data 102
Bibliography 103
ix
List of Tables
2.1 Notation used in M-step. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
3.1 Cluster demographics and characteristics of CSF biomarkers and cognitive
scores. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
3.2 Longitudinal neuropsychological associations of the clusters. . . . . . . . . . 50
3.3 Regression coefficients and p-values of studying longitudinal associations
of cognitive measures with aHV quartiles (Quartile 1 corresponds to the
lowest volume, whereas Quartile 4 is the highest). . . . . . . . . . . . . . . . 52
3.4 Summary of characteristics of clusters. . . . . . . . . . . . . . . . . . . . . . . 55
4.1 Longitudinal cognitive score difference between two subgroups . . . . . . . 87
B.1 Names of 80 ROIs used in Chapter 3. . . . . . . . . . . . . . . . . . . . . . . . 100
B.2 Names of 34 ROIs used in Chapter 4. . . . . . . . . . . . . . . . . . . . . . . . 101
x
List of Figures
1.1 (A) Schema of analyzing group difference to find disease effects. (B) Under-
lying heterogeneity of disease effects, mixed with covariates effects. . . . . . 5
1.2 Multi-atlas region of interest segmentation flowchart. . . . . . . . . . . . . . 10
2.1 (A) The problem setting: X is the reference distribution and Y is the patient
distribution. (B) Our model assumption: X is transformed into a distribu-
tion X′, covering the distribution Y, by a set of K different transformations. 15
2.2 Atrophy patterns introduced (in red). . . . . . . . . . . . . . . . . . . . . . . 26
2.3 Simulated age effect on the normalized total volume. As age increases, the
total volume linearly decreases and the variance of the ROI volumes increases. 27
2.4 Box plot of dice scores on synthetic data between ground truth labels and
outputs of clustering methods: (a) K-means, (b) K-means with profile, (c) Hi-
erarchical clustering, (d) Hierarchical clustering with profile, (e) CHIMERA-
affine, (f) CHIMERA-duo, and (g) CHIMERA-trans. . . . . . . . . . . . . . . 29
xi
2.5 Box plot of dice scores on dementia dataset between ground truth labels
and outputs of clustering methods: (a) K-means, (b) K-means with pro-
file, (c) Hierarchical clustering, (d) Hierarchical clustering with profile, (e)
CHIMERA-affine, (f) CHIMERA-duo, and (g) CHIMERA-trans. . . . . . . . 31
3.1 Cluster probabilities for subjects classified within each cluster. The vertical
red line indicates a 0.5 probability of belonging to the cluster. . . . . . . . . . 43
3.2 Venn diagram depicting the number of subjects classified tightly or loosely
into each cluster. Subjects with a probability > 0.5 were included within a
single cluster, whereas subjects with a highest cluster probability < 0.5 are
depicted in the interphase of the two top clusters. . . . . . . . . . . . . . . . 44
3.3 VBM between the identified clusters and the CN reference group for the
ADNI-1 (A) and ADNI-GO/2 cohorts (B). Color scale represents the effect
size of gray matter RAVENS maps of each comparison between a cluster
and CN individuals. Red indicates greater atrophy (lower volume). Effect
size maps are thresholded at false discovery rate (FDR) adjusted p-value of
0.05. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.4 VBM between clinical groups (MCI and AD) and CN reference group in the
ADNI-1 (A) and ADNI-GO/2 cohorts (B). Color scale represents the effect
size of gray matter RAVENS maps of each comparison between a cluster
and CN individuals. Red indicates greater atrophy (lower volume). Effect
size maps are thresholded at false discovery rate (FDR) adjusted p-value of
0.05. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
xii
3.5 VBM between patient clusters, stratified by adjusted hippocampal volumes,
and CN reference group in the ADNI-1 (A) and ADNI-GO/2 cohorts (B).
Color scale represents the effect size of gray matter RAVENS maps of each
comparison between a cluster and CN individuals. Red indicates greater
atrophy (lower volume). Effect size maps are thresholded at false discovery
rate (FDR) adjusted p-value of 0.05. Quartile 1 represents the lowest volume,
whereas Quartile 4 is the highest. . . . . . . . . . . . . . . . . . . . . . . . . . 49
3.6 (A) Progression from MCI to AD stratified by MRI-defined clusters. (B) Pro-
gression from MCI to AD based on aHV quartiles. Quartile 1 represents
lowest volume, whereas Quartile 4 is the highest. . . . . . . . . . . . . . . . 50
3.7 Longitudinal cognitive changes in ADAS-Cog13, memory and executive
composite scores in MCI subjects stratified by MRI-defined clusters. . . . . . 51
3.8 Standardized yearly MRI changes observed in CN subjects and MCI subjects
belonging to the four identified clusters. A total of 124 CN, 57 Cluster 1, 44
Cluster 2, 18 Cluster 3 and 40 Cluster 4 subjects were included in the analysis
in ADNI-1 (A). 84 CN, 15 Cluster 1, 17 Cluster 2, 17 Cluster 3 and 13 Cluster
4 subjects were included in the analysis in ADNI-GO/2 (B). . . . . . . . . . 53
3.9 Prevalence of clusters as a function of age. (A) number of subjects with 5-
year brackets, (B) relative frequency of clusters, fitted with cubic splines. . . 54
3.10 Cognitive longitudinal changes based on aHV quartiles. Quartile 1 repre-
sents lowest volume, whereas Quartile 4 is the highest. . . . . . . . . . . . . 62
xiii
4.1 HELIOS takes as input a longitudinal dataset (illustrated in (a) by coloring
all time points of one subject the same), a set of uniform cubic B-spline bases
spanning the entire time range (shown in (b)), and the number of subgroups
(K=2 here). Given these, HELIOS operates by simultaneously (c) estimating
the subgroup-specific global trajectories as an optimal linear combination of
the four bases, and (d) assigning each subject to the global trajectory that is
most similar to it. The similarity is evaluated after accounting for differences
in the vertical direction through the use of offset variable D. At the end of
the algorithm, clustering and fitting for all subjects with respect to the two
global trajectories has been performed ((e) and (f), respectively). . . . . . . . 68
4.2 Illustration of the coefficient tensor C. Cpk denotes the coefficient vector for
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Chapter 1
Introduction
1.1 Overview
Over recent years, the advances in neuroimaging have enabled massive quantitative in-
vestigations of human brains, under normal and pathological conditions, and across the
human lifespan. The in vivo and non-invasive multi-modal brain mapping techniques
provide us with a wide array of tools of studying distinct aspects of brain structure and
function. To name a few, structural magnetic resonance imaging (sMRI) reveals high-
resolution brain anatomy for quantitative analysis of structural changes [85]; functional
magnetic resonance imaging (fMRI) helps to measure brain activity by detecting changes
associated with blood flow [138, 143]; and diffusion tensor imaging (DTI) makes it possible
to understand the properties of the brain’s white matter tracts [8].
Advanced neuroimaging methods have the potential to revolutionize our understand-
ing of the brain in order and in disorder, by providing rich multi-parametric informa-
tion, thus allowing advanced computer-aided diagnosis and prognosis. Towards this end,
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studies that aim to characterize the imaging pattern associated with a disease or a norma-
tive process are designed. For example, the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) cohort collects patients and elderly control subjects for the sake of learning the
pathological process of early Alzheimer’s disease; the Human Connectome Project (HCP)
recruits healthy young adults in order to gain knowledge of the neural pathways that un-
derlie brain function and behavior.
With imaging data acquired with different aims, a large amount of research put their
emphasis on one common problem: discovering regionally specific effects of brain pro-
cesses by proposing various analytic tools and conducting experiments on different datasets.
The variations of this problem are refined in a wide range of applications: by comparing a
group of patients and healthy controls, the pathological effect of brain disease can be de-
lineated; by observing normal subjects across a wide spectrum of age, the normative aging
effect can be quantified; by differentiating typical and non-typical developed adolescents,
aberrations from normal brain development, potentially leading to neuropsychiatric dis-
orders, can be better understood.
Mass univariate tools are often used for testing hypotheses about the regionally specific
effects. Deformation based morphometry (DBM) [20, 55] and tensor based morphometry
(TBM) [48, 127] compare deformation fields or their spatial derivatives of different pop-
ulations using statistical tools to detect specific voxel level anatomical variation within a
group. DBM and TBM both rely on highly accurate registration of brain images, that may
not always be possible given the large variation of human brains. On the other hand, voxel
based morphometry (VBM) analysis [6, 29] conducts voxel wise t-tests across groups of tis-
sue density maps of different populations to investigate focal differences in brain anatomy.
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The generation of tissue density maps is robust to small registration errors, which makes
VBM perhaps the most popular method in population neuroimaging analysis.
However, the univariate analysis performs statistical tests on a voxel by voxel, or re-
gion by region basis. Thus, these methods ignore multivariate relations between brain
regions that may best characterize population differences. Instead, multivariate pattern
analysis (MVPA) methods [7, 101] take advantage of dependencies among brain regions
which leads to increased sensitivity. The MVPA methods can be further grouped into su-
pervised and unsupervised learning approaches. 1) Supervised learning constitutes a set
of algorithms that produce hypotheses from instances with known labeling (e.g. diagnosis,
group membership), and make predictions about future instances. The supervised learn-
ing methods search for multivariate imaging patterns associated with the effect of interest.
One of the most widely used methods is support vector machine (SVM) [22], which at-
tempts to maximize the separation margin for different populations, that has been applied
to multiple brain disease classifications [84, 87, 156]. 2) Unsupervised learning focuses on
uncovering the latent structure of the imaging data. For example, principal component
analysis (PCA) [1] and independent component analysis (ICA) [70] extract multivariate
imaging signatures that can best explain the data variation, and are often applied to func-
tional imaging [11, 49, 64]; clustering methods find subgroups of individuals with different
imaging profiles [110, 115].
A common assumption behind most univariate and multivariate supervised analy-
ses is that the difference between two groups is generated by a single, often unifying
(patho)physiological process, that is characterized by a single imaging pattern. For in-
stance, there is a unique disease effect that is found by comparing patients and controls.
3
However, ample evidence has highlighted the heterogeneity of pathological phenotypes
presented by many diseases, such as Alzheimer’s disease [90, 110], Schizophrenia [43,
86, 113], Autism spectrum disorder [78, 145], and Attention-deficit hyperactivity disor-
der [158]. As a consequence, current approaches miss crucial information when describing
diseases effects. By neglecting heterogeneity, these approaches can only find differences
in the central tendency, such as a common imaging pattern of difference when compar-
ing two populations, or an average trend of brain changes when modeling longitudinal
imaging trajectories. The brain patterns described are therefore incomplete and can be
misleading in the worst case.
There exist two types of approaches for analyzing the heterogeneity in neuroimaging.
1)The first group of methods uses a priori defined neuropathological categories to iden-
tify subgroups of subjects [77, 90, 110, 139]. 2) The second group comprises unbiased
data-driven approaches to identify different patterns of pathology distribution based on
the atrophy patterns inherent to the population [114, 115, 154]. However, in the former
approaches, a priori definition of disease subtypes may be difficult to obtain (may need
autopsies for neuropathological findings), or might be quite noisy and non-specific (e.g.,
cognitive or clinical evaluations). In the latter approaches, standard unsupervised cluster-
ing methods are used to group patients along the direction associated with the largest data
variability, which may not be induced by the pathology, and it might conversely reflect
effects such as age, gender or disease stage.
A more specific characterization of anatomical heterogeneity of brain processes is likely
to lead to grouping of subjects into relatively homogeneous groups with potentially more
predictable clinical outcomes and treatment responses. Therefore, the diagnosis of brain
4
Figure 1.1: (A) Schema of analyzing group difference to find disease effects. (B) Underlying
heterogeneity of disease effects, mixed with covariates effects.
diseases can be significantly improved, and the findings can be utilized later in improv-
ing disease prognosis, precision medicine and patient recruiting for more targeted clinical
trials [83, 119].
1.2 Contributions
Towards tackling the above limitations, we proposed two unbiased data-driven approaches
that explicitly take into account heterogeneity in cross-sectional and longitudinal studies,
respectively. In summary, this work makes the following major contributions.
• We proposed a semi-supervised clustering algorithm, named CHIMERA (clustering
of heterogeneous disease effects via distribution matching of imaging patterns), for
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cross-sectional studies as illustrated in Figure 1.1. Instead of directly finding sub-
groups using standard clustering methods, we utilized information from healthy
controls to guide the clustering, by assuming the probability distribution of patients
is derived via a number of transformations of the probability distribution of healthy
controls. These transformations define imaging signatures of heterogeneous dis-
ease processes. Viewed differently, our approach clusters differences between two
datasets instead of clustering data itself. This proposed paradigm has two advan-
tages. First, compared to previous work [53], which produces clustering results on
the subject level and thus suffers from various uninteresting variations due to the co-
variates, the employed distribution matching scheme herein generates clustering on
the distribution level that helps reduce the influence of population variation signifi-
cantly. Second, the probabilistic modeling provides an intrinsic kernelized distance
metric, which allows measuring the similarity between subjects nonlinearly. Thus,
covariate effects that are often removed by an explicit linear regression step [100],
can now be taken into account in a generic and nonlinear way.
• The developed semi-supervised clustering algorithm was applied to a large dataset
of Alzheimer’s disease. We found four distinct neuroanatomical subtypes in mild
cognitive impairment and Alzheimer’s disease dementia relative to cognitive nor-
mals, which were replicable and consistent across two different cohorts. We further
analyzed in detail the cerebrospinal fluid (CSF) biomarkers, cognitive characteristics
and white matter hyperintensity (WMH) volumes of these subtypes. This appli-
cation opens the way of constructing a global dementia coordinate system, which
potentially can lead to a revolution in therapeutic innovation for neurodegenerative
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diseases.
• We extended the heterogeneity analysis to tackle longitudinal designs, where we
proposed HELIOS (parsing the heterogeneity of longitudinal imaging through inte-
grated clustering and spatiotemporally regularized spline curve fitting). To the best
of our knowledge, it is the first study that focuses on heterogeneous longitudinal tra-
jectories of multivariate imaging measures. The proposed method clusters individ-
ual trajectories aiming to find multiple global trajectories that can best describe the
brain change across the full age range of interest of the population. The trajectories
are modeled using spatiotemporal regularized splines, which 1) produces smooth
and nonlinear curves in the temporal domain; 2) introduces a biological prior to the
modeling. This method can be viewed as an enhanced version of linear-mixed effect
models with clustering on top.
1.3 Image preprocessing
Neuroimaging data obtained from the scanner cannot be used for our analysis directly. In
this section, we describe the datasets and the image preprocessing steps that were used in
all of our experiments.
1.3.1 Datasets
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
The Alzheimer’s Disease Neuroimaging Initiative (ADNI)1 is an ongoing multicenter study
designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early
1http://www.adni-info.org
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detection and tracking of Alzheimer’s disease (AD). The initial phase of ADNI (ADNI-1)
started in 2004, with $67 million funding provided by both the public and private sectors.
ADNI-1 recruited 400 subjects diagnosed with mild cognitive impairment (MCI), 200 sub-
jects with early AD and 200 elderly cognitive normal subjects. This study was extended
with ADNI-GO which added 200 participants identified as having early mild cognitive
impairment (EMCI). In 2011, ADNI-2 began with another $67 million in funding. ADNI-2
assesses participants from the ADNI-1/ADNI-GO cohort in addition to the following new
participants: 150 elderly controls, 100 EMCI, 150 LMCI (late “mild cognitive impairment”)
participants and 150 mild AD patients. A subset of the data from this study is used in
Chapter 3 to find Alzheimer’s disease subtypes.
Baltimore Longitudinal Study on Aging (BLSA)
The Baltimore Longitudinal Study on Aging (BLSA) [140] is America’s longest-running
scientific study of human aging at the National Institute on Aging (NIA). Its neuroimag-
ing sub-study began in 1994 and is currently scheduled to continue indefinitely. Approx-
imately 150 healthy elderly adults (age range: 56-85) were initially recruited and have
been followed annually with a rich radiologic examination resulting to 740 structural MRI
scans. The imaging protocol includes structural (T1-, and T2-weighted MR images) and
functional activation scans. More recently, additional subjects were included raising the
number of total imaging sessions to over 2500. Imaging data are complemented with de-
tailed neurocognitive evaluations performed under the direction of Dr. Resnick. A subset
of the data from this study is used for methodology testing in Chapter 4, where a more
extensive analysis of this dataset is described.
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1.3.2 Feature extraction from structural scans
Region of interest (ROI) volumetry
The high dimensionality of MR images hinders their analysis and interpretation. Extract-
ing region of interests (ROI) effectively reduces the dimensionality of the data in an in-
terpretable and anatomically meaningful way. We employed a multi-atlas segmentation
algorithm [38] which uses a consensus labeling framework to fuse/integrate segmenta-
tion hypotheses generated by warping a broad ensemble of labeled atlases to the target
space via the use of several warping algorithms, regularization parameters, and atlases.
The label fusion integrates two complementary sources of information: a local similarity
ranking to select locally optimal atlases and a boundary modulation term to refine the
segmentation consistently with the target image’s intensity profile. The flowchart of the
ROI algorithm is presented in Figure 1.2. In our analyses, we used this algorithm to parti-
tion the brain into approximately one hundred disjoint ROIs generated, and obtained the
volume of each ROI as a feature representation of the brain.
Tissue density maps
ROIs provide us with data in a dimension that we can easily handle in order to parse dis-
ease heterogeneity. However, in order to characterize disease processes in greater spatial
detail, we employed tissue density maps for subsequent subgroup-analyses. Towards this
end, we employed tissue density maps that allow us to characterize disease processes in
greater spatial detail. Specifically, we employed a previously published volumetric ap-
proach to generate tissue density map for group comparisons [28, 29], termed RAVENS
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Figure 1.2: Multi-atlas region of interest segmentation flowchart.
(regional analysis of volumes examined in normalized space) map. The RAVENS maps are
obtained with the following procedures. An established deformable registration method
[118] is used for warping individual images to a single subject brain template. The brain
image scans are segmented into three tissue types: gray matter, white matter and cere-
brospinal fluid [95]. RAVENS maps encode, locally and separately for each tissue type, the
volumetric changes (local expansion or shrinkage) observed during the registration. They
hence have the advantage of accounting for imperfect registration by taking the residual
(error) of the imperfect registration into account.
10
1.4 Organization of this thesis
The two main methodological contributions of this thesis are described in Chapters 2 and
4. Chapter 2 details the CHIMERA method, its performance on simulated data, and vali-
dation on real data. Chapter 3 presents the main application of CHIMERA to Alzheimer’s
disease dataset (ADNI), with a detailed analysis of the four subtypes found, including
the imaging signatures, demographics characteristics, the level of CSF biomarkers and the
cognitive performances. In Chapter 4, we describe the longitudinal approach for hetero-
geneity trajectories, validate its performance using synthetic data, and apply it to a real
dataset (BLSA). Chapter 5 summarizes all the contributions of this thesis and discusses
future work.
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Chapter 2
Clustering Imaging Patterns of
Disease Effect via Distribution
Matching
2.1 Introduction
Group analyses are ubiquitous in neuroimaging, which are commonly applied to study
the differences between populations. Typical applications include, but are not limited to,
analyses for describing disease effects by comparing patients and controls [44, 79, 167],
studies for characterizing aging effects by comparing old and young subjects [17, 59], as
well as efforts to characterize brain development by comparing subjects of different ages
[57, 143]. Statistical group analyses are carried out throughout studies using diverse types
of images, including functional MRI [148, 162], structural MRI [29, 50, 67], and diffusion
tensor imaging [60, 144].
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Most of the group analyses assume that the members of a group share a common imag-
ing pattern that differentiates them from the other group. For example, they assume that
there is a unique disease effect that is found by comparing patients and controls. Such an
approach can only find changes in the central tendency, i.e., a “common denominator”.
However, various clinical studies have highlighted the heterogeneity of pathological phe-
notypes presented by many diseases, such as Alzheimer’s disease [110, 114], schizophre-
nia [43, 105], autism spectrum disorder [145], attention-deficit hyperactivity disorder [158]
and cancer [54, 98]. In such cases, where we can assume that two groups differ by one pat-
tern in one sub-population, and a different pattern in another sub-population, a “common
denominator” is at best incomplete, and at worst misleading. As a consequence, current
approaches are limited in the presence of heterogeneity as they miss crucial information
when modeling disease effects.
Towards addressing the challenges posed by heterogeneity, the use of clustering meth-
ods to partition the population of patients has been proposed [80, 97, 115, 160]. However,
direct clustering of patient images puts emphasis on the similarities/distances between in-
dividuals, rather than on the heterogeneity of the disease effect itself. Hence, they produce
clusterings which reflects the largest contributors of data variability, such as brain size,
participant sex, and scanner/protocol discrepancies, and may fail to cluster the individu-
als according to their pathology subtypes. In order to mitigate this problem, general linear
regression [100, 116] is commonly applied to residualize imaging features with respect to
covariates. Nevertheless, the effectiveness of this approach suffers from two limitations: 1)
the linear assumption may not hold thus the regression might introduce more noise to the
analysis; 2) covariates may correlate to the disease such that removing the covariate effect
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may undermine the strength of disease effect analysis.
We propose to address the aforementioned limitations by proposing a novel regular-
ized clustering method based on establishing a mapping between two statistical distribu-
tions. The first statistical distribution corresponds to the reference population, e.g., healthy
controls, cognitive stable participants, or normally developing adolescents. The second
distribution corresponds to the patient population that has been deviated from the refer-
ence population under the influence of a number of effects that we would like to describe.
These effects may include heterogeneous disease processes, pathophysiological processes
leading to cognitive decline, or aberrations from normal brain development. As shown in
Figure 2.1, we model the heterogeneous effects as a set of transformations from the refer-
ence to the patient distribution, where each transformation corresponds to one pathology
subtype. The transformations are found by matching patient and reference distributions,
while taking covariates such as age, sex, scanner, etc. into account (which exactly covari-
ates are to be used depends highly on the specific application/study). In other words,
given that a 70-year-old male Alzheimer’s disease patient would have been a 70-year-old
male control had he been spared from the disease, the transition between these two states
is considered to be the disease effect. This covariate-informed matching reduces the con-
founding influence of the covariates, which leads to a better description of the disease
effects.
2.2 Method
Let us assume that the dataset contains M normal control (NC) samples X = {x1, ..., xM}
and N patient samples Y = {y1, ..., yN}. Let us assume that the samples are described by
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(A) (B)
Figure 2.1: (A) The problem setting: X is the reference distribution and Y is the patient
distribution. (B) Our model assumption: X is transformed into a distribution X′, covering
the distribution Y, by a set of K different transformations.
two sets of features: a set of D1-dimensional imaging features: xvm, yvn ∈ RD1 ; and a set
of D2-dimensional covariate features (these are known variables, such as age, sex, tumor
type, treatment type): xcm, ycn ∈ RD2 . For the sake of simplicity, we will denote the samples
in the compact vector forms: xm = (xvm, xcm) and yn = (yvn, ycn).
Without loss of generality, let us consider the samples as points in the imaging space
(Figure 2.1). In this setting, the pathology can be viewed as the difference between Y
(patient) and X (NC) point distributions. In order to model this difference, we adopt a
probabilistic framework where the pathologic transition between the two groups is mod-
eled as a transformation T, mapping the NC distribution to the patient distribution. One
key assumption of the proposed framework is that we have collected enough data to al-
low us to adequately describe the NC population, and that the estimated anatomy of the
patients would have been covered by the NC distribution, had they been spared of the
disease. These assumptions imply that all patients can be associated with NCs, and con-
versely, the transformed NC points cover the entire set of patients. In this setting, we can
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estimate the transformation T by matching the patient and NC distributions. The distri-
bution matching paradigm consists of distance measures of imaging features, thus it is
convenient to introduce covariates into the matching criteria by combining imaging and
covariate-specific distances in a multi-kernel way [91].
The distribution matching problem is formulated as a maximum a posteriori (MAP)
optimization problem. Thus, the optimal transformation is estimated by minimizing the
following energy:
E(X,Y,Θ) = −L(X,Y,Θ) +R(Θ), (2.1)
where Θ denotes the parameters of our model, such as transformations that are applied to
X for generating Y, L is the log-likelihood of the distributions X and Y given the parame-
ters, while a regularization/penalty R improves the stability/reliability of the estimation.
These two parts are presented in detail in the next two sections.
2.2.1 Log-likelihood term
Due to the heterogeneity of the effects of a given disease, the pathological transition might
take several directions. Therefore, T is modeled using multiple possible transformations,
where each of them represents a pathological direction of imaging change. The trans-
formed NC samples are denoted as X′ = [x′1, · · · , x′M ], where the imaging feature xvm is
transformed to T(xvm), while the covariate feature xcm remains the same:
x′m = T(xm) = (T(x
v
m), x
c
m). (2.2)
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Based on the hypothesis that the origins of patient samples are covered by the NC sam-
ple space, we deduce that if we apply the pathological process model to the NC samples
X, the transformed NC point distribution X′ will cover the patient point distribution Y,
as shown in Figure 2.1(B).
The matching of distributions Y and X′ is found by a variant of the coherent point
drift algorithm [111]. Each point x′m is considered as a centroid of a spherical Gaussian
cluster. All the clusters are assumed to have the same variance σ2, which is inferred by
the method. Points yn are treated as i.i.d. data generated by a Gaussian Mixture Model
(GMM) [15] with equal weight P (x′m) =
1
M for each cluster. The similarity between the
two distribution is measured by the data likelihood of this mixture model, as presented in
Equation (2.3).
In order to take covariate features into account, we adopt a multi-kernel setting. The
distance between two points is measured by RBF kernels, where the kernel size of covariate
features is r times larger than the kernel size of the imaging features. As a result, the
likelihood of data Y generated by centroids X′ can be described as follows:
P (X,Y) =
N∏
n=1
M∑
m=1
P (x′m)P (yn|x′m)
=
N∏
n=1
M∑
m=1
1
M
rD2/2
(
√
2piσ)D1+D2
· exp
{‖yvn −T(xvm)‖2 + r‖ycn − xcm‖2
−2σ2
}
. (2.3)
During our experiments, the hyper-parameter r was determined by the ratio of total vari-
ance of these two features.
We assume that there are K pathology directions T1, ..., TK for a given disease. We
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define the transformation for one NC point to the patient space as:
T(xvm) =
K∑
k=1
ζkmTk(x
v
m). (2.4)
Ideally, if the disease subtypes were generated by distinct groups of NC points, ζkm would
be 1 for the transformation corresponding to the disease subtype that affects xm, and value
0 otherwise. In this work, we assume that patients with different pathologies might corre-
spond to the same point in the space of NC distribution, and we relax the variable ζkm to
sum up to 1 for each m. This relaxation leads us to consider the transformation T for each
NC point xm as a convex combination of all possible transformations Tk.
Linear transformation were chosen to model Tk, in order to derive analytical solutions
for the distribution matching. Each Tk was described by a pair of parameters (Ak, bk) ∈
(RD1×D1 ,RD1):
T(xvm) =
K∑
k=1
ζkm(Akx
v
m + bk), (2.5)
where
∑
k ζkm = 1 and ζkm ≥ 0 for all m.
During our experiments, three different kinds of Ak matrices were chosen: (1) full ma-
trices (CHIMERA-affine), (2) diagonal matrices, in order to restrict the transformations to
the combinations of scaling and translations (CHIMERA-duo) and (3) the identity, in order
to consider only the translations bk (CHIMERA-trans).
Introducing the definition of transformations Tk into Equation (2.3) leads to the follow-
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ing expression for the log-likelihood of the data:
L(X,Y,Θ) =
N∑
n=1
log
M∑
m=1
1
M
rD2/2
(
√
2piσ)D1+D2
exp
{
r‖ycn − xcm‖2
−2σ2
}
· exp
{
‖yvn −
∑K
k=1 ζkm(Akx
v
m + bk)‖2
−2σ2
}
. (2.6)
2.2.2 Model regularization
As defined in the previous section, in an imaging feature space of dimension D1, the
dimension of parameter space of CHIMERA-affine is in the order of O(D21), while for
CHIMERA-duo and CHIMERA-trans is in the order of O(D1). In the low sample size set-
tings that are typically observed in medical imaging studies, this large dimension yields
ill posed problems. This issue is commonly mitigated by regularizing/penalizing the pa-
rameters of the transformations [41, 132]. We have adopted this approach, which improves
also the generalization and the robustness of our model. In order to derive an analytical
solution, we have chosen to penalize the Frobenius norm of Ak − I and the `2 norm of bk,
where I is the identity matrix. This regularization, is equivalent to posing Gaussian priors
for the parameters.
R(Θ) = λ1
2σ2
∑
k
‖bk‖22 +
λ2
2σ2
∑
k
‖Ak − I‖2F . (2.7)
Beside the explicit regularization term R, our model can also be considered as being “im-
plicitly” regularized. Instead of focusing on the points at the border between the different
groups, like support vector machine [22] and relevance vector machine [149], our model
always consider the entire point distributions. We aim, in that way, to reduce the sensi-
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tivity of clustering produced with respect to the individual subject variability (population
variability).
2.2.3 Optimization
In this work, we have used an Expectation-Maximization algorithm [15, 108] for opti-
mizing the parameters Θ = (A,b, ζ, σ2) of our model, where A = {A1, · · · , AK} and
b = {b1, · · · , bK}. The algorithm introduces latent variables z indicating the posterior
probability of data point n for each mixture component m, qnm = q(zn = x′m|yn). By doing
so, it provides a lower bound of the log-likelihood [15]:
F0 =
∑
n,m
qnm log
(
P (yn, x
′
m)
qnm
)
. (2.8)
The energy E is minimized via an iterative scheme. In each iteration t, the algorithm al-
ternates between calculating in the E-step the expected value of q with respect to the pa-
rameters obtained in the previous iteration Θ(t−1), and updating Θ(t) by minimizing the
objective function (Equation (2.10)) in the M-step.
During our experiments, at the initialization, the parameters σ2 was set to the mean
distance between datasets X and Y, ζ was set to be uniformly distributed for each xm,
each Ak was set to the identity matrix I, while the translation term bk was sampled from a
normal distribution N (0, 1). The E-step and M-step were performed as follows.
E-Step:
Using the parameters Θ(t−1) estimated in the previous M-step, Equation (2.8) was op-
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timized at qnm = P (zn = x′m|yn):
qnm =
exp
(‖yvn−∑k ζkm(Akxvm+bk)‖22+r‖ycn−xcm‖22
−2σ2
)
∑M
i=1 exp
(‖yvn−∑k ζki(Akxvi+bk)‖22+r‖ycn−xci‖22
−2σ2
) . (2.9)
M-Step:
We constructed our objective energy function F(Θ) as an upper bound of our energy
function E . The minimization of F(Θ) leads to the minimization of E [112]:
F(Θ) = 1
2σ2
∑
m,n
qnm
(
‖yvn −
∑
k
ζkm(Akx
v
m + bk)‖22 + r ‖ycn − xcm‖22
)
+
N(D1 +D2)
2
log σ2 +
λ1
2σ2
∑
k
‖bk‖22 +
λ2
2σ2
∑
k
‖Ak − I‖2F , (2.10)
subject to
K∑
k=1
ζkm = 1 for m = 1, ...,M, 0 ≤ ζkm ≤ 1.
The objective function is not globally convex but jointly convex in each parameter. Hence,
we propose an iterative procedure by minimizing the objective sequentially with respect
to σ2, ζ, A and b. We derived a closed form solution for σ2, A and b by setting the
derivative of the objective function to zero. ζ was optimized using an advanced projected
gradient descent algorithm that preserves the sum of the ζkm [39]. The notation used in
the following equations is presented in Table 2.1. We define d(u) as a square matrix with
the diagonal elements to be the vector u, and 1 as a vector with all elements being 1 with
appropriate dimension.
21
Notation Dimension Description
Xv D1 ×M mth column is T(xvm)
Xc D2 ×M mth column is xcm
Yv D1 ×N nth column is yvn
Yc D2 ×N nth column is ycn
A D1 ×KD1 concatination of Ak, A = [A1, · · · , AK ]
b D1 ×K concatination of bk, b = [b1, · · · , bK ]
ζ K ×M [ζ]km = ζkm, ith row is ζi·, mth column is ζ·m
Q N ×M [Q]nm = qnm
Table 2.1: Notation used in M-step.
1. Update σ2: The estimation of the variance is updated as follows:
σ2 =
[
tr(Yvd(Q1)Y
T
v − 2YvQXTv +Xvd(QT1)XTv )
+ tr(Ycd(Q1)Y
T
c − 2YcQXTc +Xcd(QT1)XTc )
+ λ1
∑
k
‖bk‖22 + λ2
∑
k
‖Ak − I‖2F
]/
N(D1 +D2). (2.11)
2. Update A: depending on the nature of the matrix A, the following cases are dis-
cerned:
• WhenAk is full matrix, let Cij be the (i, j)th block ofC, andG = [G1, · · · , GK ],
where Cij and Gi are obtained by:
Cij = Xvd(Q
T1)d(ζi·)d(ζj·)X
T
v (2.12)
Gi = λI+YQd(ζi·)X
T
v −Bd(QT1)d(ζi·)XTv . (2.13)
By setting the derivative of F(Θ) with respect to A to be 0, we can calculate A
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using Equation (2.14):
A = G(λI+C)−1. (2.14)
• When Ak is a diagonal matrix: we first denote Ai = d(ai1, ..., aiD) and we will
calculate all jth diagonal elements for all k together, aj ∈ RK×1. Let Wjrs be
the (r, s)th element of K ×K matrix Wj , which can be derived as:
Wjrs =
∑
m
x2mj
∑
n
qnmζrmζsm. (2.15)
Let zm =
∑
k ζkmbk, and U
j
i be the ith element of K × 1 vector Uj :
Uji =
∑
m,n
qnmζim(zm − yn)jxmj . (2.16)
Then, we can obtain the update of aj as follows:
aj = (W
j + λI)−1(λ1−Uj). (2.17)
3. Update b:
Let Vrs be the (r, s)th element of K ×K matrix V, and Zr be the rth row of K ×D1
vector Z, respectively:
Vrs =
∑
qnmζrmζsm (2.18)
Zr =
∑
m,n
qnmζrm(y
v
n −
∑
k
ζkmAkx
v
m). (2.19)
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Thus, we can derive b as:
bT = (λI+V)−1Z. (2.20)
4. Update ζ:
We adopted a gradient descent method for optimizing ζ, and projected the obtained
vector to the `1 simplex in order to satisfy the sum-to-one constraint. Let Hm be the
hessian for the mth column of ζ, which can be obtained element wise using:
∂F
∂ζim
=
1
σ2
∑
n
qnm(y
v
n −
∑
k
ζkm(Akx
v
m + bk))
T (−Aixvm − bi)
Hmij =
∂2F
∂ζimζjm
=
1
σ2
∑
n
qnm(Ajx
v
m + bj)
T (Aix
v
m + bi). (2.21)
Given the above hessian estimate, we performed gradient descent, and projected
the new vector to the `1 simplex: [39].
ζnew·m = ζ
old
·m − (Hm + µI)−1
∂F
∂ζ·m
. (2.22)
During our experiments, we stopped iterating when the objective difference between
two iterations reached a predefined tolerance, which was set to 0.01. Because the EM al-
gorithm only guarantees a local minimum solution, we ran the optimization several times,
and we kept the solution with the lowest energy value.
The next section explains how a clustering can be derived from the coefficients ζkm and
the posteriors qnm which were estimated during the optimization, and how a new sample
can be assigned to these clusters.
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2.2.4 Clustering
The coefficients ζkm can be considered as the probability, for the NC sample xm, to undergo
the transformation Tk. Let P (yn|xm) be the likelihood of a patient sample yn to be associ-
ated with xm. Then, the likelihood of a given patient sample, yn, to have been generated
by the transformation Tk can be estimated by:
Pk(yn) =
∑
m
P (yn|xm)ζkm. (2.23)
Because the posteriors qnm are proportional to P (yn|xm), with a common denominator for
each n (Equation (2.9)), they can be used for partitioning the patient samples according
to their main transformation. Thus, each patient yn can be assigned to the label ln, which
corresponds to the largest likelihood:
ln = argmax
k
Pk(yn) = argmax
k
∑
m
qnmζkm. (2.24)
As long as the ζkm are stored, the label can be estimated for a novel data s by: (1) computing
the likelihood P (s|xm) based on the distances between the novel sample s and the trans-
formed controls X′, (2) computing Pk(s), and (3) obtaining the label ls = argmaxk Pk(s).
This strategy was adopted for clustering clinical data during our experiments.
2.3 Experiments
This section presents the experiments that were conducted for validating our approach. We
compared first our approach with two standard clustering methods, i.e., K-means [97] and
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Figure 2.2: Atrophy patterns introduced (in red).
Ward hierarchical clustering [160], as well as two variants of these methods, on synthetic
data and a real dataset of dementia patients with known subtypes. The promising results
obtained incited us to analyze a clinical dataset where the ground truth is unknown.
2.3.1 Synthetic data
Our method was first validated using synthetic data simulating the effect of age and dis-
ease on brain volume. The brain was divided into 20 regions of interest (ROIs), where the
atrophy was described by a normalized volume between 0 (the most serious atrophy) and
1 (largest possible ROI volume).
The simulated data was generated as follows:
1. 1000 samples were generated independently. For each sample, 20 ROI volumes
were sampled randomly from a normal distribution, N (1, 0.1). In addition, each
sample was associated with a random age, sampled from a uniform distribution
between 55 and 85.
2. Age effect was introduced for each ROI volume and every sample, by subtracting
the atrophy volume. The ROI volume atrophy was simulated by a normal distribu-
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Figure 2.3: Simulated age effect on the normalized total volume. As age increases, the total
volume linearly decreases and the variance of the ROI volumes increases.
tion N (0.01(t − 55), 0.005(t − 55)), where t is the age. This simulation corresponds
to a linear volume decrease with age (slope) equal to 0.01 per year; and a variance
increase of slope equal to 0.005 per year.
3. The samples were randomly separated into two 500-sample groups, corresponding
to a control group and a patient group. The patient group was further divided into
two sub-groups of 250 samples. In each patient group, we introduced an atrophy
pattern induced by a 15% decrease in volume in pre-selected regions. Some of the
regions selected were common across the subgroups, while some others were dis-
tinct. This was done to simulate the effect of two distinct, but overlapping, variants
of a same neurodegenerative disease. The two atrophy patterns are shown in Figure
2.2.
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4. The ROIs volumes were then normalized independently, by scaling them between
0 (the most atrophied sample ROI volume) and 1 (the largest sample ROI volume).
The simulated data with heteroscedastic age effect is plotted in Figure 2.3. For both groups,
the normalized total volume decreases as age increases. The patient group has smaller total
volume due to the disease effect. However as the variance increases, the disease effect is
overwhelmed by the age effect.
We compared our model with K-means [97] clustering and Ward hierarchical cluster-
ing [160]. However, standard clustering methods do not have access to the information of
control group as CHIMERA does. For a fair comparison, we considered therefore two sup-
plementary variants of these clustering methods. Similar to pattern-based morphometry
[53], we computed a “profile” for each patient subject. That is, we computed the difference
vector between each patient point and its nearest neighbor in the control group according
to the Euclidean distance between features. These profiles were clustered instead of the
original patient data. In these analysis, a general linear regression (GLM) [100] was per-
formed on the imaging features in order to remove the age effects prior to the clustering.
The three variants of our method were applied to the synthetic data. We set model parame-
ters as follows, CHIMERA-affine: (λ1, λ2) = (10, 100); CHIMERA-duo: (λ1, λ2) = (10, 10);
and CHIMERA-trans: λ1 = 10.
The simulation was repeated 100 times independently. All the methods were applied
to each simulated data set, with K = 2. The Dice score [35] of overlap between the ground
truth and the clustering labels was generated for each run, and the box plots for different
methods are presented in Figure 2.4. Given that the dice score is 0.5 when the labels are
assigned randomly, our method performs better than clustering methods and their profile-
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Figure 2.4: Box plot of dice scores on synthetic data between ground truth labels and out-
puts of clustering methods: (a) K-means, (b) K-means with profile, (c) Hierarchical cluster-
ing, (d) Hierarchical clustering with profile, (e) CHIMERA-affine, (f) CHIMERA-duo, and
(g) CHIMERA-trans.
based variations. CHIMERA-duo outperformed the other CHIMERA variants. This result
indicates that CHIMERA-duo model contains enough degrees of freedom for capturing
the differences between patient and control groups, which cannot be expressed as a pure
translation. At the same time, the model is much smaller than the affine model, which is
hard to regularize.
2.3.2 Neurodegenerative disease data
Before using our method for exploring unknown heterogeneous imaging patterns, we vali-
dated our approach on a dementia dataset containing patients suffering from different dis-
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eases generating distinct imaging patterns. We used a dementia clinical dataset of 317 T1
structural MRI scans corresponding to 148 Alzheimer’s Disease (AD) patients, 91 Parkin-
son’s Disease (PD) patients and 78 Normal Controls (NC). The images were skull-stripped
[37], co-registered [118] and multi-atlas ROIs were generated [38], as described in Chapter
1. We listed the names of regions used in Appendix Table B.1. The volumes of 80 ROIs
were calculated, as well as the volume of brain lesions present in the data [92]. The age
and gender of each subject were utilized as covariate features.
The performances of the seven methods described in section 2.3.1 were estimated by
performing one hundred 10-folds cross-validations on the dataset. For each cross-validation,
the patient samples were partitioned randomly into ten folds. For each fold, the cluster-
ing was first established by using normal control samples and the remaining 90% patients.
The 10% test samples of the fold were then assigned clustering labels. For K-means and
Hierarchical clustering, the assignment was based on the distance to cluster centers. For
our approach, the assignment procedure is explained in section 2.2.4. After this assign-
ment, the dice score between the known subtype labels and the labels produced by the
clustering methods was computed for the samples of the fold. A dice score for the entire
cross-validation was obtained by averaging the dice scores obtained for the ten folds. Run-
ning the cross-validation one hundred times with different partitions of the patient data
produced the distribution of dice scores shown in Figure 2.5. There is a significant perfor-
mance gap between our approach and standard clustering methods. CHIMERA-duo and
CHIMERA-trans worked comparably well, while the performance of the CHIMERA-affine
model were a little lower.
This experiment confirms that our approach can identify distinct imaging patterns cor-
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Figure 2.5: Box plot of dice scores on dementia dataset between ground truth labels and
outputs of clustering methods: (a) K-means, (b) K-means with profile, (c) Hierarchical
clustering, (d) Hierarchical clustering with profile, (e) CHIMERA-affine, (f) CHIMERA-
duo, and (g) CHIMERA-trans.
responding to clinically heterogeneous populations using real imaging data. Thus, we
used CHIMERA to investigate the existence of disease subtypes in Alzheimer’s disease.
The results of our analysis are presented in Chapter 3.
2.4 Conclusion and discussion
CHIMERA is a novel generative clustering framework, which is capable of for identify-
ing disease subtypes of heterogeneous diseases. CHIMERA relies on a point distribution
mapping, while taking into account the influence of nuisance covariates, thus overcoming
several methodological limitations of existing methods for the analysis of disease hetero-
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geneity. We discuss here three main aspects that have not been presented in detail in the
previous sections. We also discuss a way to address the main limitation of our current
framework.
First, the soft assignment performed by our model provides a rich information about
the pathology. Each normal/control point is transformed with a probability distribution ζ
by all possible transformations. This notion implies that a healthy subject might make a
transition to a diseased state via various pathological patterns/processes. The clustering
of patients is based on the posterior probability q and ζ. Instead of a hard assignment
for clustering outputs, our approach produces a probability-based soft assignment, which
might better describe the disease effects.
Second, the framework is modular. In this work, we have used a linear transformation
with scaling and translation that has O(D) degrees of freedom. Since the sample sizes
of most neuroimaging studies are relatively small, we might improve the performance of
the model by choosing a more constrained transformation. For instance, the transforma-
tion could be represented by the displacement of a few reference samples [111]. Such a
transformation would exhibit much fewer degrees of freedom, which could further im-
prove the robustness of the optimization/clustering. Hierarchical transformations could
also be implemented, similarly to [118], for reducing the computational burden and/or
better constraining the transformation.
Thirdly, we integrate the covariate features in a multi-kernel way. Our framework does
not make any explicit assumption on the effect of covariates where GLM on the contrary
assumes that the covariates have a linear relationship with the imaging features. With this
strategy, our framework mitigates the effect of covariates non-linearly and softly, rather
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than the common approach of stratifying and matching populations based on covariates
before group analyses.
The large dimension of the transformations involved in our current framework consti-
tutes its main limitation. The optimization instability induced was partially addressed by
penalizing the transformations. However, this approach would not be suitable for high di-
mensional data, such as voxel-level image maps [58], or voxel-wise transformations. The
use of sparser transformations, as explained above, will help reduce the dimension of our
model. Stricter penalties, such as `21 and `1 penalties, can be investigated in the future.
However, we think that dimensionality reduction will probably remain necessary, in or-
der to maintain the stability of the optimization and reduce the number of local optima.
Another limitation of our current linear transformation formulation is that it does not take
into account the covariance structure of the data, such as covariation between left and
right side of the brain. Though we got symmetric results in the experiments, it might be
beneficial to introduce this constraint into the framework. Lastly, the Euclidean distance
adopted in the framework implicitly treats features with the same weight. This limita-
tion could be addressed by using the Mahalanobis distance instead. These aspects will be
further investigated in the future.
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Chapter 3
Capturing Heterogeneity in
Prodromal Alzheimer’s Disease
3.1 Introduction
Alzheimer’s disease (AD) presently affects over 5.5 million individuals in the United States
and is projected to affect 13.8 million of people of age 65 and older by the mid-century
[9, 65]. It poses a substantial healthcare, financial, and caregiver burden [69] to the commu-
nity and healthcare system. Importantly, Alzheimer’s disease is the most common cause
of dementia, where several coincident pathologies, mainly vascular lesions, limbic TAR-
DNA binding protein-43 (TDP-43) and Lewy body related pathology, also account for the
cognitive symptoms of dementia subjects [131, 150, 153, 154, 165, 168]. The presence of dif-
ferent brain pathologic lesions and the variations in cognitive reserve, genetic background,
and environmental exposures, can lead to differential vulnerability. This, in turn, can lead
to large variations in the clinical presentation and course of the subjects. Therefore, it can
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be expected that a group of cognitively impaired subjects is composed of different sub-
types. Each subtype would present a specific disease course and characteristics. While AD
is not treatable, an accurate identification of the disease in its early stage could be proved
crucial towards leading to more effective therapeutic interventions. Towards this end, re-
search into biomarkers that can precisely quantify the subtle and complex structural and
functional changes that are induced in the brain during the early stages of AD is of particu-
lar interest and importance. Many studies have taken part in developing tools or applying
established methodologies that use neuroimaging to improve diagnosis of AD.
Despite the increasing evidence of population heterogeneity [90, 110] and the poten-
tial benefits from accurately characterizing it, most of the imaging analysis approaches
ignore phenotypic heterogeneity and define patterns of structural or functional changes
based on clinical categorical definitions and summarizing them with a single imaging pat-
tern. On the one hand, mass univariate tools such as voxel based morphometry and its
variants [6, 10, 18, 81, 82, 169] are adopted in quantifying the differences between AD pa-
tients and normal control populations. On the other hand, multivariate pattern analysis
[26, 42, 84, 106, 156] seeks to improve the specificity and sensitivity of computer-aided di-
agnosis by encoding relations across multiple variables within a discriminative imaging
pattern. However, these imaging patterns are either incomplete or worst misleading, in
the presence of heterogeneity.
Characterizing the heterogeneity of Alzheimer’s disease using neuroimaging would al-
low elucidating the underlying neuropathological processes. By identifying patients with
distinct imaging signatures, the disease diagnosis would be improved through precision
diagnostic, which would further enhance therapeutic innovation in clinical trials through
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appropriate patient recruitment.
Recognizing the limitations of the case-control setting, previous efforts have focused
on using a priori defined neuropathological categories to identify subgroups of patients
[77, 90, 110, 139]. However, such neuropathological or clinical categories may not be re-
liable enough for accurately distinguishing disease subtypes [93, 102]. Importantly, these
approaches rely on a clinical “intuition”, thus being biased and prone to human error.
Unbiased data-driven approaches show promise to be able to identify different patterns
of pathology distribution based on the atrophy patterns inherent to the population [114,
115, 154]. However, commonly used standard clustering methods tend to group patients
along the direction associated with the largest data variability, which may not be induced
by the pathology, and which might reflect effects such as age, gender or disease stage. To
avoid this, we should be steering the clustering algorithm to focus on the neurodegener-
ation patterns that drive cognitive impairment. Such a clustering is more likely to lead to
grouping patients into relatively homogeneous groups, with potentially more predictable
clinical outcomes and treatment responses.
In this chapter, we investigated the heterogeneity of neurodegeneration in mild cogni-
tive impairment (MCI) and AD relative to cognitively normal (CN) individuals, by lever-
aging the methodology described in Chapter 2, and capitalizing on the large datasets of
MCI and AD patients from ADNI (ADNI-1 and ADNI-GO/2). This work can comple-
ment and contribute to recently proposed dimensional approaches, such as the A/T/N
(amyloid-β/tau/neurodegeneration) AD staging system [71], by evaluating and catego-
rizing heterogeneity of disease-related neurodegeneration patterns in a data-driven way.
Four distinct neuroanatomical subtypes were found in MCI and AD dementia relative to
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CN, where the patients across ADNI-1 and ADNI-GO/2 cohorts showed consistent neu-
rodegenerative signatures. Subtypes in this context are mainly meant to define the main
dimensions of the heterogeneity of AD, rather than imply distinct imaging phenotypes. To
investigate that, we studied in detail the cerebrospinal fluid (CSF) biomarkers, cognitive
characteristics and white matter hyperintensity (WMH) volumes of these subtypes.
3.2 Materials and methods
3.2.1 Subjects
A total number of 1243 AD Neuroimaging Initiative (ADNI)1 participants were included
in the study, including 760 ADNI-1 subjects (213 CN, 370 late MCI (LMCI), and 177 AD
subjects) and 483 ADNI-GO/2 subjects (186 CN, 160 LMCI, and 137 AD). Early MCI sub-
jects from the ADNI-GO/2 were excluded because this group was only recruited in ADNI-
GO/2. CN subjects included subjects with normal cognition, independently of the pres-
ence of memory complaints. Diagnoses of MCI and AD were established as described in
[103, 121, 120]. The data for this study was downloaded in December 2015. The ADNI
datasets have been extensively reviewed in [161]. To evaluate differences in cognitive per-
formance, we studied the previously developed memory composite score [24], the execu-
tive composite score [56], and the Boston naming test scores. Median follow-up length for
ADNI-1 and ADNI-GO/2 MCI subjects was 161.0 (1st quartile: 105.4 - 3rd quartile: 315.0)
and 156.3 (1st quartile: 106.5 - 3rd quartile: 159.1) weeks, respectively.
1http://www.adni-info.org
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3.2.2 Cerebrospinal fluid (CSF) collection and measurement
CSF samples were processed as previously described [136, 137]. Aβ1−42 and total tau (t-
tau) were measured using the multiplex xMAP Luminex platform (Luminex Corp, Austin,
TX) with Innogenetics (INNO-BIA AlzBio3; Ghent, Belgium; for research use-only reagents)
immunoassay kitbased reagents.
3.2.3 MRI acquisition and processing
Acquisition of 1.5-T MRI (for ADNI-1) and 3.0-T MRI (for ADNI-GO/2) data at each study
site followed a previously described standardized protocol that included volumetric 3D
MP-RAGE (magnetization-prepared rapid gradient-echo imaging [109]) or Sagittal MP-
RAGE with variable resolution around the target of 1.2mm isotropically. The scans went
through the following correction methods: gradwarp, B1 calibration, N3 correction [141],
and (in-house) skull-stripping [37]. See (www.loni.usc.edu/ADNI) and [72] for details.
For the heterogeneity analysis, T1 structural MRI images of all subjects were segmented
into 80 anatomical regions of interest (ROIs). The ROI labels were obtained using the
method described in Chapter 1. The names of the ROIs used are listed in Appendix Table
B.1. To assess longitudinal neuroimaging changes, another set of surface ROI volumes pro-
vided by ADNI were used, which were processed using the FreeSurfer2 software package
version 4.4 [125, 126]. For visualizing disease patterns, regional tissue volumetric maps,
termed RAVENS [29] were generated. Further details regarding image processing can be
found in Chapter 1. We used the CN group data for linearly regressing age and gender
from the RAVENS maps of the entire dataset. Adjusted hippocampal volume (aHV) was
2http://surfer.nmr.mgh.harvard.edu/
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calculated and matched across ADNI-1 and ADNI-GO/2 cohorts using a set of matched
MRIs as previously described in [155]. All the subjects were then divided into four quar-
tiles in order to perform the stratification analysis based on hippocampal atrophy, which
is considered to be a sensitive biomarker of dementia.
3.2.4 White matter hyperintensities (WMH)
WMH were segmented using different approaches in ADNI-1 [134] and ADNI-GO/2 [32].
The method applied on ADNI-1 utilized PD, T1, and T2 MR images. This method is based
on a Bayesian Markov random field approach, where the joint posterior probability of the
presence of WMH at each voxel is maximized. The posterior probability consists of a like-
lihood computed from image intensities, a spatial prior that regularizes the location of
WMHs, and a contextual prior that encourages neighbor voxels to have the same labels.
The method applied on ADNI-GO/2 utilized FLAIR and T1 images. This method operates
first by co-registering the FLAIR MR image to the T1 image, and then performing inhomo-
geneity correction. The binary WMH mask is then estimated based on histogram fitting
and thresholding at 3.5 standard deviations above the mean signal in brain matter distri-
bution. The WMH mask is further refined by taking into account spatial prior and tissue
class constraints in a Bayesian approach.
3.2.5 Heterogeneity and voxel based morphometry analysis
In this study, ADNI-1 and ADNI-GO/2 datasets were combined in order to delineate more
consistent pathological imaging patterns. However, the structural MRI scans from these
two cohorts have many discrepancies, such as different scan protocols and magnetic field
39
strengths. We took these discrepancies into account during our analyses by introducing the
original recruitment cohort (ADNI-1 versus ADNI-GO/2) as a covariate in our model, in
addition to age and gender. As a result, the patient and normal control distributions were
matched within each cohort separately, but the pathological effects captured by CHIMERA
were shared across datasets. We performed a 10-fold cross-validation using the combined
dataset to evaluate the robustness of the method, which showed an 84.1% agreement. In
addition, we applied our clustering approach separately in the ADNI-1 and ADNI-GO/2
cohorts, which showed a 63% and 74% overall agreement with the combined approach,
respectively.
3.2.6 Statistical analysis
The demographic variables, APOEε4 genotype (apolipoprotein E type 4 [21]), CSF biomarker
levels, cognitive test scores and WMH volumes were compared across clusters. For cate-
gorical variables, the Fisher exact test was used to identify differences between groups. In
case of significant differences, the conducted pairwise comparisons between clusters were
adjusted for multiple comparisons using the Bonferroni procedure. For quantitative de-
mographic variables (e.g. age) an ANOVA analysis was conducted, followed by a Dunn
test. For the clinical and CSF biomarker measures, an ANCOVA analysis was performed,
which included age, gender, years of education and APOEε4 genotype as covariates. In
case of significant differences, the Dunn’s post-hoc test was performed. When the AN-
COVA requirements were not met, a Box-Cox transformation was applied to the data. A
longitudinal neuropsychological analysis was conducted for LMCI patients (AD subjects
were excluded due to short follow-up) using mixed effect models that included subjects
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and time as random effects and age, gender, time, APOEε4 presence and years of educa-
tion as fixed effects. A Cox hazards model including age, gender, APOEε4 presence and
years of education as covariates, was fitted for comparing the conversion of LMCI patient
to AD in the different clusters. For the evaluation of the profile of longitudinal changes
in MRI volumes, individual mixed effects models that included age, gender, time and
APOEε4 as covariates, were applied to estimate the yearly ROI volumetric changes in CN
subjects and patients belonging to the different clusters. Baseline and 2nd year MRI scans
were compared for this purpose, and ROI values were standardized to compare findings
across the different areas. Analyses were performed using R v. 3.2.2 [122]. The visual-
ization of imaging signatures of derived clusters (i.e., the clusters found by CHIMERA),
of clinically-defined (AD/MCI/AD+MCI) groups, and of aHV-defined (aHV quantiles)
groups was performed via VBM [6, 23] on RAVENS maps.
3.3 Experiments and results
3.3.1 Cluster demographic and genetic characteristics
We adopted a cross-validation strategy to find the optimal hyperparameters (i.e. num-
ber of clusters and regularization coefficient) of CHIMERA [36]. For each combination of
hyper-parameters, 100 runs of leave-10%-out clusterings were performed. During each
clustering, a random subset of 90% of the patient samples and all the normal control sam-
ples were used for generating the transformations and defining the patient clusters. The
remaining 10% patient samples were assigned to one of the estimated clusters, based on
their proximity with the transformed controls (Equation 2.24). We measured the Adjusted
41
Rand Index (ARI), which indicates the reproducibility of clustering memberships, between
all the pairs of the 100 clusterings obtained for each hyperparameter set, and averaged the
ARI for each clustering. The hyperparameters that yielded the best reproducibility were
chosen to produce clustering memberships herein.
We finally partitioned the entire set of ADNI patients into four clusters that included
in each case subjects from ADNI-1 and ADNI-GO/2. Subjects in different ADNI cohorts,
but within the same cluster, exhibited similar atrophy patterns. The characteristics of clus-
ters identified in ADNI-1 and ADNI-GO/2 cohorts are summarized in Table 3.1. In all
ADNI cohorts, Cluster 2 subjects were older and had a greater proportion of AD dementia
subjects compared to Cluster 1.
3.3.2 Cluster membership confidence
In our main analysis, we assigned each subject to the cluster with the highest probabil-
ity. For most of the subjects, cluster membership was assigned with a probability ≥ 0.5.
However, in the remaining cases, membership was assigned with a probability < 0.5. The
“tightest” cluster was Cluster 2 (87% subjects had a probability ≥ 0.5), whereas Cluster 3
was the loosest one (66% subjects had a probability ≥ 0.5) (Figure 3.1), with most of the
loose cases being close to Cluster 1. We summarize these findings using a Venn diagram
in Figure 3.2.
3.3.3 Cross-sectional clinical and biomarker associations
CSF Aβ1−42 defined groups, WMH volume and the studied cognitive measures differed
between the four clusters (Table 3.1). Post-hoc group comparisons identified similar results
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Figure 3.1: Cluster probabilities for subjects classified within each cluster. The vertical red
line indicates a 0.5 probability of belonging to the cluster.
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Figure 3.2: Venn diagram depicting the number of subjects classified tightly or loosely
into each cluster. Subjects with a probability > 0.5 were included within a single cluster,
whereas subjects with a highest cluster probability < 0.5 are depicted in the interphase of
the two top clusters.
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across cohorts. Subjects in Cluster 2 and 3 included a higher frequency of subjects with
pathological CSF Aβ1−42 values. Cluster 2 and 3 subjects presented worse performance in
the memory composite and in ADAS-Cog (Alzheimer’s Disease Assessment Scale - Cog-
nitive Subscale) compared to Cluster 1. In addition, Cluster 2 subjects had worse executive
composite, higher p-tau values, and greater WMH volume compared to Cluster 1 subjects.
Only in ADNI-GO/2 did the clusters differ in terms of CSF t-tau values (Cluster 1 had
lower values than Cluster 2 and 3).
3.3.4 Group-wise VBM results
The group-wise VBM results are presented in Figure 3.3. Cluster 1 showed the least
amount and extent of atrophy. In the ADNI-1 cohort, the atrophy was mainly localized
in the temporal lobe with additional involvement of the posterior cingulate cortex. How-
ever, in ADNI-GO/2 it was statistically indistinguishable from CN. Interestingly, Cluster 4
showed moderate localized atrophy in the hippocampus and the anterior-medial temporal
cortex, without any significant involvement beyond these regions. Conversely, Cluster 2
and 3 showed widespread involvement, extending to the temporal, parietal, and occipital
lobes in addition to subcortical gray matter. However, they presented markedly different
patterns, as Cluster 2 presented relatively most severe temporal atrophy, whereas Cluster
3 exhibited a more diffuse atrophy pattern, with a comparatively less dominant involve-
ment of the temporal lobe compared to Cluster 2. Group comparisons based on baseline
diagnosis and aHV quartiles are shown in Figure 3.4 and Figure 3.5, respectively.
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Figure 3.3: VBM between the identified clusters and the CN reference group for the ADNI-
1 (A) and ADNI-GO/2 cohorts (B). Color scale represents the effect size of gray matter
RAVENS maps of each comparison between a cluster and CN individuals. Red indicates
greater atrophy (lower volume). Effect size maps are thresholded at false discovery rate
(FDR) adjusted p-value of 0.05.
3.3.5 Longitudinal changes
Cluster 2 and 3 showed a faster progression from MCI to AD, and a steeper cognitive de-
cline in the studied cognitive measures compared to Cluster 1 (Table 3.2, Figure 3.6(A) and
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Figure 3.4: VBM between clinical groups (MCI and AD) and CN reference group in the
ADNI-1 (A) and ADNI-GO/2 cohorts (B). Color scale represents the effect size of gray
matter RAVENS maps of each comparison between a cluster and CN individuals. Red in-
dicates greater atrophy (lower volume). Effect size maps are thresholded at false discovery
rate (FDR) adjusted p-value of 0.05.
Figure 3.7). Similarly, Cluster 2 and 3 showed a more pronounced longitudinal cognitive
decline than Cluster 1 (Figure 3.6(A)). Interestingly, whereas the rate of change of the ex-
ecutive profile was similar in Cluster 2 and 3 (p-value=0.75), Cluster 3 showed a lower
rate of memory decline compared to Cluster 2 (p-value=0.039). In none of the analyses did
Cluster 4 differ from Cluster 1. Tabel 3.3 and Figure 3.6(B) summarize the results for aHV
quartiles.
Longitudinal MRI changes in the different ROIs and groups are summarized in Figure
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Figure 3.5: VBM between patient clusters, stratified by adjusted hippocampal volumes,
and CN reference group in the ADNI-1 (A) and ADNI-GO/2 cohorts (B). Color scale rep-
resents the effect size of gray matter RAVENS maps of each comparison between a cluster
and CN individuals. Red indicates greater atrophy (lower volume). Effect size maps are
thresholded at false discovery rate (FDR) adjusted p-value of 0.05. Quartile 1 represents
the lowest volume, whereas Quartile 4 is the highest.
3.8. In this figure, it can be appreciated that the Cluster 1 shows a similar pattern of atrophy
as the CN group in all areas except the temporal lobe, where the atrophy rate is more
pronounced for Cluster 1. Cluster 2 and 3 showed the fastest rates of atrophy, with the
former showing a faster temporal atrophy, whereas in the latter case the preponderance
was frontal. Finally, Cluster 4 showed an intermediate pattern.
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Cluster 1 Cluster 2 Cluster 3 Cluster 4
MCI to ADa Ref. 2.26 (<0.0001) 1.87 (0.0024) 1.27 (0.21)
ADAS-Cog13 Ref. 0.20 (<0.0001) 0.09 (0.023) 0.04 (0.31)
Memoryb Ref. -0.11 (<0.0001) -0.06 (0.030) 0.004 (0.86)
Executiveb Ref. -0.12 (<0.0001) -0.11 (0.0005) -0.04 (0.17)
Only late MCI subjects were included due to short Alzheimer’s disease (AD) subjects follow-up.
Age, gender, education and APOE were included as covariates.
a Hazard ratio (P-value).
b Regression coefficient (P-value).
Table 3.2: Longitudinal neuropsychological associations of the clusters.
(A) (B)
Figure 3.6: (A) Progression from MCI to AD stratified by MRI-defined clusters. (B) Pro-
gression from MCI to AD based on aHV quartiles. Quartile 1 represents lowest volume,
whereas Quartile 4 is the highest.
3.3.6 Prevalence of clusters as a function of age
We also investigated the prevalence of each of the 4 clusters, as a function of age. Figure
3.9 shows the number of subjects in each cluster, averaged over a 5-year bracket around
each age, as well as the clusters relative frequency (which takes into account the variable
number of subjects per age group) as a function of age. Curves were fitted using cubic
splines with 3 control points. Taking into consideration potential boundary effects in these
fits (small number of subjects on either end of the age spectrum), Figure 3.9 generally
shows that the proportions of Cluster 2 and 3 increase and decrease, respectively, steadily.
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Figure 3.7: Longitudinal cognitive changes in ADAS-Cog13, memory and executive com-
posite scores in MCI subjects stratified by MRI-defined clusters.
Cluster 4 is relatively stable throughout this age range, whereas the proportion of Cluster
1 seems to decrease steadily after the age of 63.
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Quartile 1 as reference
Memory Composite Executive Composite
Coefficient p-value Coefficient p-value
Quartile 1 Ref. Ref. Ref. Ref.
Quartile 2 -0.130 <0.0001 -0.122 <0.0001
Quartile 3 -0.147 <0.0001 -0.130 <0.0001
Quartile 4 -0.131 <0.0001 -0.154 <0.0001
Quartile 4 as reference
Memory Composite Executive Composite
Coefficient p-value Coefficient p-value
Quartile 1 -0.016 <0.0001 0.154 <0.0001
Quartile 2 0.001 0.97 0.032 0.36
Quartile 3 0.131 0.60 0.024 0.51
Quartile 4 Ref. Ref. Ref. Ref.
Table 3.3: Regression coefficients and p-values of studying longitudinal associations of
cognitive measures with aHV quartiles (Quartile 1 corresponds to the lowest volume,
whereas Quartile 4 is the highest).
3.4 Discussion
We evaluated the heterogeneity of neurodegeneration present in MCI and AD, relative to
CN individuals, by applying the proposed pattern analysis and machine learning method,
which was described in Chapter 2, on data from ADNI. We found four distinct groups that
best summarized this neuroanatomical heterogeneity. Besides having markedly different
atrophy patterns, these groups also differed in the frequency of AD-like CSF Aβ1−42 and
tau levels, as well as in their clinical profiles (Table 3.4). In particular, Cluster 1 included in-
dividuals with generally normal anatomy, the lowest frequency of subjects with abnormal
CSF Aβ1−42 levels, normal CSF-tau levels, least baseline cognitive impairment and slowest
rates of cognitive decline. Conversely, Cluster 2 was consistent with the typical AD-like
neuroanatomical patterns and high frequency of AD-like CSF Aβ1−42 levels, and fastest
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(A)
(B)
Figure 3.8: Standardized yearly MRI changes observed in CN subjects and MCI subjects
belonging to the four identified clusters. A total of 124 CN, 57 Cluster 1, 44 Cluster 2, 18
Cluster 3 and 40 Cluster 4 subjects were included in the analysis in ADNI-1 (A). 84 CN, 15
Cluster 1, 17 Cluster 2, 17 Cluster 3 and 13 Cluster 4 subjects were included in the analysis
in ADNI-GO/2 (B).
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Figure 3.9: Prevalence of clusters as a function of age. (A) number of subjects with 5-year
brackets, (B) relative frequency of clusters, fitted with cubic splines.
cognitive decline affecting executive and memory cognitive domains. Cluster 3 showed
greater cortical atrophy in parietal and dorsolateral frontal cortex with proportionately
lesser involvement of the limbic cortex, compared to Cluster 2. Although Cluster 3 was as-
sociated with fast cognitive decline, this decline was more marked for the executive rather
than the memory composite score, which is consistent with the imaging findings. Notably,
Cluster 3 MCI individuals did not show further progression to AD after four years, al-
though this has to be interpreted cautiously due to the small number of subjects followed
for that long a period. Finally, Cluster 4 included individuals with localized atrophy in the
hippocampus and medial temporal lobe, although cognitive changes did not differ from
the ones observed in Cluster 1.
In the A/T/N AD staging system [71], each dimension has only two status, pres-
ence/positive or absence/negative, which are determined by a single dichotomous classi-
fication/thresholding. This dichotomous classification may be appropriate for CSF Amyloid-
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Neuroanatomical
atrophy pattern
Alzheimer’s
disease-like CSF
Aβ1−42 levels
Cognitive decline
Cluster 1 Mild or none; non-focal Lowest frequency Least steep
Cluster 2 Widespread, greater
temporal involvement
Higher frequency Steepest for memory and
executive
Cluster 3 Widespread, global Higher frequency Steepest for executive,
intermediate for memory
Cluster 4 Localized, temporal Lower frequency Least steep
Table 3.4: Summary of characteristics of clusters.
β and tau values (“A” and “T” dimensions). These are typically considered as a single
linear measure for AD, which is line with previous pathology studies that have described
the typical Amyloid-β deposition in the brain and brainstem [146]. However, we consider
that the structural imaging neurodegeneration patterns (“N” dimension) can be hetero-
geneous. Thus, the binarized “N” dimension in [71] might be an oversimplification that
does not take advantage of the data richness offered by current neuroimaging approaches.
As we describe below, none of the clusters captured specifically Amyloid-β positivity or
negativity, although the clusters showed differences in the frequency of Amyloid-β pos-
itivity. It is well known that different neurodegenerative conditions can manifest similar
clinical presentations leading to imperfect clinic-pathological correlations [152]. Therefore,
it is not surprising that this extends to the patterns of brain atrophy captured by structural
MRI, which ultimately represent neurodegeneration, which in turn is clinically expressed
as impairment in different cognitive functions. Even in ADNI, which is a clinical trial-
oriented cohort recruiting subjects with a typical AD profile, there has been a significant
neuropathological heterogeneity in patients with classic amnestic AD clinical presentation
[153].
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The variability revealed by our analysis indicates that a dimensional approach to neu-
rodegeneration in cognitively impaired subjects, including MCI and AD dementia stages,
is important and consistent with previous observations of atypical AD presentations [4,
25, 62, 117]. The different patterns we observed might also relate to several coincident
neurodegenerative and vascular pathologies [5, 131, 150, 152].
This dimensional approach is important not only for a personalized prognosis, but also
for recruiting more homogeneous groups of individuals into clinical trials and tailored
interventions. For example, MCI individuals who fall into Cluster 1 have relatively nor-
mal brain anatomy and better prognosis, suggesting that their cognitive decline might be
highly influenced by factors other than AD pathology. Interestingly, although this group
has a decreasing relative frequency with increasing age, as expected, it remains a signif-
icant ∼20% of this population in ages 80 and older. Individuals in Cluster 2 present the
typical AD profile and have rapidly increasing relative frequency with increasing age (Fig-
ure 3.9(B)). Individuals along the dimension of Cluster 4 are particularly interesting. These
subjects showed focal and pronounced atrophy in the temporal lobe with preserved brain
volumes elsewhere. Although subjects in this group showed a relatively slower cogni-
tive decline, long-term follow-up indicated a steady progression from MCI to dementia.
These individuals are likely to represent an earlier disease stage, as indicated by a higher
frequency of LMCI subjects as opposed to AD dementia at the baseline visit which might
later develop to a pattern similar to the one observed in Cluster 2. These changes would
be consistent with Braak’s tau pathology staging [16]. Cluster 4 could, therefore, be at the
relatively early stage of disease, which is potentially an excellent target for clinical trials
aiming to slow down disease progression. It is important to note that the cognitive perfor-
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mance of these individuals was comparable to the subjects in Cluster 1, indicating that cog-
nitive summary scores might not always capture regional differences in atrophy patterns
and lack the ability to detect heterogeneous atrophy patterns. Interestingly, Cluster 4 had a
rather stable relative frequency as a function of age (Figure 3.9(B)), which is consistent with
the interpretation of this group as newly emerging, early stage AD cases who later move
into Cluster 2 as new cases take their place in Cluster 4. Longitudinal analyses are required
to further test this hypothesis. Finally, Cluster 3 subjects presented predominantly execu-
tive function decline and a more widespread and non-focal pattern of atrophy. Therefore,
this cluster might be likely representing atypical AD presentations [117], or a mixture of
pathologies, which are commonly present in demented subjects, and are associated with
a relatively greater impairment of executive function [150, 152, 153, 154]. The decreasing
prevalence of this group with increasing age is consistent with prior work that more “cor-
tical”, or atypical presentations of AD, occur more commonly at a younger age of onset
[46]. In addition, the profile of Cluster 3 is consistent with previous results indicating that
hippocampal volume alone might be neither a sensitive, nor a specific biomarker in early
disease stages [27, 151, 155]. This especially might be the case for atypical non-amnestic
presentations without underlying AD pathology. Our results indicate that the entire pat-
tern of brain atrophy needs to be taken into consideration. This also further emphasizes
the potential value of such a clustering in clinical trial recruitment, as Cluster 3, similar
to Cluster 2, represents a group that has a high likelihood of AD pathology based on CSF
Aβ1−42 levels, but in which memory and hippocampal measures would be less effective as
markers of disease progression than, for example, executive measures.
A somewhat unexpected finding of our study was the fact that Cluster 3 had signifi-
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cantly lower WMH load, compared to Cluster 2 and 4, and even to Cluster 1 in ADNI-1,
although it was characterized by fast executive decline. This was contrary to our initial
expectation that this group might present more of the small vessel ischemic disease phe-
notype, which would have been consistent with more widespread atrophy. It appears that
Cluster 3 might reflect either more cortical presentations of AD, or potentially other kinds
of comorbidities or mixed pathologies, which result in the atypical AD pattern of atrophy.
For example, the initial study of ADNI autopsy cases identified that cases with coincident
Lewy related pathology had a relative large executive impairment compared to memory
scores [153]. This unexpected result could be partly explained by the exclusion of subjects
with a high baseline Hachinski score, or imaging findings consistent with an infarct, which
would result in excluding cases with overt vascular pathology from ADNI.
Somewhat unexpected was also the fact that Cluster 4 had significant WMH load. Since
this group’s imaging pattern seems to mainly indicate early and likely relatively purer AD
pathology, we did not expect to have significant WMH load. This finding is consistent with
a recently reported association between high WMH volume and temporal lobe atrophy in
a large population based study [63]. Moreover, it has been described that the hippocampus
might present relatively higher vulnerability to vascular changes [107]. Cluster 2 also dis-
played AD-like atrophy and high WMH load. These results indicate that lesion load and
AD-like atrophy seem to be correlated, to some extent, even at seemingly early disease
stages. This finding is in agreement with growing literature that shows an association be-
tween WMH load and AD pathology, albeit our study is not able to determine whether this
association is due to shared risk factors or to a more direct relationship in pathophysiology.
Overall, Cluster 2 and 3 were characterized by the relatively highest frequency of
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subjects with AD-like CSF Aβ1−42 values, whereas Cluster 1 presented a higher number
of subjects with normal CSF Aβ1−42 values. On the other hand, the frequency of sus-
pected non-amyloid pathology (SNAP) cases differed between the different clusters (4.2%
- 36.7%), which indicates that the AD specificity varies across clusters. These findings
confirm that different pathologies (or combinations of pathologies) [153] can also be char-
acterized by classical amnestic MCI and AD dementia clinical presentations, while these
similarities can even extend to MRI patterns of atrophy.
Finally, the longitudinal MRI changes did also differ between the clusters. Clusters
2 and 3 showed the fastest decline. Areas with the fastest decline corresponded to the
same areas that were more involved in baseline comparisons, further reinforcing baseline
findings. Interestingly, Cluster 1 showed a large overlap with the CN group, except in
the temporal lobe, where Cluster 1 showed a faster progression. Therefore, Cluster 1 may
mainly have AD pathology, but probably representing an early stage, at least for part of
this group.
Taken together, our findings suggest that there is remarkable heterogeneity in the pat-
terns of brain atrophy that distinguish CN from MCI and AD patients, even in a relatively
homogeneous group of subjects, such as the one recruited in ADNI. In particular, a rela-
tively normal group (Cluster 1) displays only mild atrophy. The cross-sectional and lon-
gitudinal profile of this cluster suggests that it is heterogeneous, with some individuals
likely to progress to the other two clusters (Cluster 2 and Cluster 3), and some likely to
remain stable for a relatively long time. Individuals belonging to the Cluster 4 are likely
to be at early and rapidly progressing AD disease stages. Individuals in Cluster 3 either
represent more cortical presentations of AD, perhaps reflected by their younger age, or
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mixed pathologies other than small vessel ischemic disease. Importantly, some of these
individuals are likely to progress to predominantly AD dementia, and others to a more
executive-prominent cognitive decline and dementia. In addition to shedding light into
the neuroanatomical heterogeneity of MCI and AD, our results suggest that patient recruit-
ment into clinical trials might benefit from a finer characterization of the neuroanatomical
phenotypes. Finally, our results suggest that a rigorous and quantitative dimensional neu-
roanatomical approach is necessary for neurodegenerative diseases, in view of the under-
lying heterogeneity seen, even in relative strictly selected groups of subjects like the ones
of ADNI.
Figure 3.4 further underlines the limitations of commonly used voxel-based methods in
characterizing the spectrum of neuroanatomical alterations in MCI and AD based on a pri-
ori diagnostic definitions that rely on disease severity. In particular, these figures indicate
that voxel-based analysis of regional volumes detects the same form of brain atrophy pat-
tern in AD dementia and MCI, with the MCI pattern being more spatially restricted and
less pronounced. This picture is consistent with a single typical progression pattern for
AD, presenting a milder involvement in MCI, thereby largely missing the remarkable het-
erogeneity unveiled by our results. Given that the underlying pathophysiological mech-
anisms leading to brain atrophy are complex and heterogeneous, personalized treatment
decisions and selection into treatment trials are likely to benefit significantly from the di-
mensional approach followed herein.
The work presented in this chapter differs substantially from recent clustering-based
approaches [114]. Our methodology [36] used herein does not apply direct clustering to
the images themselves, which could cluster individuals according to anatomical character-
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istics, such as brain or ventricular size, demographics, and other covariates, which are not
related to disease effects. In contrast, CHIMERA estimates the disease effects by grouping
the differences between patients and controls, after having matched for these confounding
covariates. Also, previous findings [114] were derived from a much smaller sample drawn
only from ADNI-1, which also uses a limited number of features to perform the cluster-
ing (i.e., 11 basic features, including brain, ventricular and hippocampal volumes). As a
consequence, previous results seemed to have been significantly affected by outliers in the
data (e.g. Cluster 4 of the aforementioned publication included only seven individuals of
likely very extreme measurements, which are arguably outliers). However, our findings
are generally in agreement with [114]. This is particularly true for the existence of a sub-
population of MCI which is almost entirely normal in all measures, and the existence of
a subpopulation, which seems to display a typical AD-like pattern. Albeit their results
reveal additional heterogeneity.
Another previous study described three patterns of neurofibrillary tangle deposition
based on a priori definitions [110]. These groups were described as hippocampal-sparing,
limbic-predominant and typical AD, and were later characterized using structural MRIs
[163]. Our findings also confirm the presence of subpopulations in MCI and AD-dementia
subjects with different degrees of limbic and extra-limbic pathologies, which in some cases
do not follow the pattern expected based on tau neurofibrillary tangle tau staging [16]. In
our study, cases with a lesser limbic involvement (Cluster 3) were also younger than cases
with typical AD atrophy, despite exhibiting larger dorsolateral prefrontal cortex atrophy.
As noted above, Cluster 3 is likely to include patients with more cortical disease in young
onset cases as described in [46].
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Figure 3.10: Cognitive longitudinal changes based on aHV quartiles. Quartile 1 represents
lowest volume, whereas Quartile 4 is the highest.
Grouping subjects based on aHV quartiles led to a linear staging of patient atrophy, pri-
marily reflecting hippocampal volume, as expected. However, these maps failed to reveal
the remarkable heterogeneity highlighted by our clustering analysis, including Cluster 3,
which was characterized by substantial and widespread cortical atrophy, but relatively
preserved hippocampal volumes. We have also calculated conversion and longitudinal
cognitive models, as shown in Figure 3.6(B) and Figure 3.10. Although four aHV quartiles
were studied, these analyses showed that patterns effectively represented two subgroups.
Specifically, one subgroup comprised 75% of the subjects who progressed rapidly, while
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the second subgroup consisted of 25% of the subjects, who remained more stable. This
suggests that while hippocampal volume is an important biomarker of memory decline,
it is not sufficiently rich or specific in capturing the heterogeneity of AD. In order to dis-
entangle the heterogeneity, our analysis suggests that it is important to delineate imaging
patterns throughout the brain.
Limitations of this study are: 1) the smaller sample size for ADNI-GO/2 compared
to ADNI-1, which led to small numbers in some clusters; 2) the relative homogeneity of
the subjects recruited in the study, which were recruited either as late MCI subjects with
AD-like clinical presentation or early AD dementia type subjects. Future studies should
expand to more heterogeneous populations.
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Chapter 4
Parsing Heterogeneous Longitudinal
Trajectories
4.1 Introduction
Longitudinal studies are indispensable tools for tracking structural or functional brain
changes over time [30, 47, 61, 76, 88, 142]. In longitudinal studies, each subject serves
as his/her own control, and change is assessed directly over repeated evaluations. This is
in contrast to cross-sectional approaches, where change is evaluated by comparing differ-
ent individuals, and thus may be confounded by normal variations across the population.
The within-subjects comparisons in longitudinal studies have the advantage of reducing
inter-subject variability, which results in increased statistical power for quantifying change
over time. This allows the extraction of subtle brain imaging patterns that accurately char-
acterize temporal dynamics.
The above properties make longitudinal studies particularly suitable for studying the
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dynamics of pathological processes [76, 128]. As a consequence, longitudinal designs have
found numerous applications in computational neuroimaging. Among their most impor-
tant applications, one may cite the identification of the neuroimaging pattern that reflects
disease processes [40, 130, 133, 147], the accurate description of age trajectories of brain re-
gion volumes [104, 164], as well as the study of the associations between cognitive change
and brain structure and function [40, 123, 135].
Longitudinal studies typically make use of analytical tools that fall into two main cat-
egories. The first group of methods puts emphasis on differentiating distinct longitudi-
nal processes by performing group comparisons between categorizations of subjects (e.g.,
comparing individuals before and after treatment). These categorizations are commonly
based on clinical diagnosis [19, 73], or on individual characteristics extracted from the
imaging data [66, 99]. The second group of approaches, on the other hand, focuses on
describing the brain temporal dynamics by employing linear/nonlinear mixed effects re-
gression models [12, 13, 14, 124, 157]. The mixed effects model can effectively model the
global trend that spans the time range of the entire study as fixed effect, while also ac-
counting for individual variability using random effect variables.
The overarching assumption behind the above methods is that the population of inter-
est is a homogeneous entity, resulting from a single unifying (patho)physiological tempo-
ral process, which is characterized by a single imaging signature. This assumption effec-
tively ignores ample evidence for the heterogeneous nature of both neurodegenerative dis-
eases [90, 110] and neuropsychiatric disorders [43, 78, 113]. In such cases, the members of a
heterogeneous population may present different phenotypes, which may be characterized
by multiple distinct disease processes. As a consequence, common approaches that ignore
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heterogeneity may only find a common/average direction of longitudinal brain changes. If
we assume that two groups, or two conditions, differ by one longitudinal pattern in a sub-
population and a different longitudinal pattern in another subpopulation, such a common
denominator is at best incomplete, and at worst misleading. Accurately identifying and
quantifying heterogeneous longitudinal trajectories is essential for elucidating underlying
heterogeneous neurobiological mechanisms, for improving disease diagnosis and progno-
sis, for targeted treatment interventions, as well as for enhancing therapeutic innovation.
In order to disentangle the heterogeneity of temporal (patho)physiological processes,
clustering of longitudinal trajectories can be performed. There is a rich literature on the
topic of curve clustering [2, 51, 52, 94]. However, most approaches [2, 51, 52] commonly
require the trajectories to have the same length in order to be able to compare them effec-
tively. This requirement is hard to fulfill in longitudinal studies, where subjects may be
recruited at different time points, and may also have different lengths of follow-up. On the
other hand, methods that can account for uneven-length trajectories, such as [94], seek for
common groups of directions based on linear segments of individual trajectories. The con-
tinuity of individual curves is disregarded, which is crucial when applied to longitudinal
studies, and thus not applicable to our needs.
To address the above limitations, we propose a novel method for analyzing the HEt-
erogeneity of Longitudinal Imaging trajectOries by integrating clustering and spatiotem-
poral Spline modeling of trajectories, termed HELIOS. The proposed framework estimates
simultaneously multiple trajectories at the population level, and performs unsupervised
multivariate clustering by assigning each individual to the population trajectory, whose
segment fits best the individual’s data. Population trajectories span the full time range
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of the study and capture the temporal dynamics of respective variables/features. In esti-
mating global trajectories, we assume that each individual trajectory is a segment of the
global trajectory. This allows us to account for differences in recruiting time and length
of follow-up. Given this assumption, the method attempts to reconstruct the global tra-
jectories using the partial information from all the subjects’ individual trajectories. Global
trajectories are modeled using spatiotemporally regularized cubic B-splines. Polynomial
splines are used to account for non-linearities, while temporal regularization controls the
variance of the estimated trajectories. We additionally introduce spatial regularization to
take advantage of the spatial structure of the data toward improving model estimation
and statistical power. Multiple trajectories per variable/feature are estimated to model the
underlying heterogeneous processes. As a consequence, heterogeneity of brain changes is
modeled as multiple sets of trajectories, with each set representing a distinct multivariate
imaging pattern of longitudinal change. Heterogeneity is dissected by clustering subjects
based on how well corresponding segments of the global trajectories fit their own individ-
ual data time points. The resulting optimization problem is solved through Expectation-
Maximization (EM) [15], where a multi-initialization strategy is used and the clustering
result that yields the lowest objective is kept.
4.2 Method
In this chapter, we analyze the trajectories of imaging features across the temporal di-
mension, by modeling non-linear trajectories using cubic B-splines. In order to take into
account the underlying heterogeneity, we assume that there are K subgroups of subjects
following different longitudinal multivariate patterns of change. Each multivariate pat-
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Figure 4.1: HELIOS takes as input a longitudinal dataset (illustrated in (a) by coloring all
time points of one subject the same), a set of uniform cubic B-spline bases spanning the
entire time range (shown in (b)), and the number of subgroups (K=2 here). Given these,
HELIOS operates by simultaneously (c) estimating the subgroup-specific global trajecto-
ries as an optimal linear combination of the four bases, and (d) assigning each subject to the
global trajectory that is most similar to it. The similarity is evaluated after accounting for
differences in the vertical direction through the use of offset variable D. At the end of the
algorithm, clustering and fitting for all subjects with respect to the two global trajectories
has been performed ((e) and (f), respectively).
tern is described by a set of feature trajectories, and each subject is assigned to the sub-
group whose imaging trajectories best represent its own individual changes. The above
procedure is illustrated in Figure 4.1, where longitudinal trajectories are estimated for two
groups.
This concept is formulated in a probabilistic setting in our framework. Optimal trajec-
tories and clustering are estimated simultaneously by minimizing the following objective:
E(X, θ1, . . . , θK) = L(X, θ1, . . . , θK) +R(θ1, . . . , θK),
where L is the least squares loss of data X fit by the cubic B-splines. The splines are de-
scribed usingK sets of parameters Θ, while the regularizationR of Θ encourages temporal
smoothness of the splines and incorporates spatial covariance structure of the imaging fea-
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tures. We present the two parts in detail in the following sections.
4.2.1 Loss term
Let the longitudinal study include N subjects, x1, · · · , xN , where each subject xi has ni
imaging scans acquired at time points ti1, ti2, · · · , tini . The number of follow-up scans
varies for different subjects. An illustration of the longitudinal dataset is shown in Figure
4.1(a). For each imaging scan, a number of P features (e.g., region volumes, tissue den-
sities, activation maps, etc.) are extracted. We denote the pth feature of jth time point of
subject xi by x
tij
ip .
In this work, the longitudinal trajectories of every feature are modeled using B-splines,
which can be represented by an M dimensional basis vector B(t), which spans the full
time range of the study. Each spline can be uniquely described using a coefficient vector
C of dimension M , i.e., the parametrized B-spline can be expressed by B(t)C. For the
experiments herein, we chose cubic B-splines (M=4, see Figure 4.1(b)), which provides us
with sufficient non-linearity to model the trajectories, but also with a reasonable number
of parameters to optimize. Given time t, the bases of cubic B-splines can be obtained with
the pre-defined functions:
B(t) =
[
t3 t2 t 1
]
· 1
6

−1 3 −3 1
3 −6 3 0
−3 0 3 0
1 4 1 0

. (4.1)
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Figure 4.2: Illustration of the coefficient tensor C. Cpk denotes the coefficient vector for
a single spline; the Ĉp cross section contains K sets of coefficients; the C˜k cross section
contains P sets of coefficients.
All the spline coefficients in our approach are represented together by a 3D tensor C ∈
RK×P×M , which is illustrated in Figure 4.2. Every column of C, Cpk ∈ RM×1, corresponds
to a single spline that describes the trajectory of the pth feature of cluster k. To ease the
notation, we denote two relevant cross sections of the tensor C by Ĉ and C˜. Specifically,
for each feature p, there is a set of K coefficients Ĉp ∈ RM×K , describing the behavior of
this feature in K different subgroups. On the other hand, for each subgroup k, there is a
set of P coefficients C˜k ∈ RM×P , which describe the multivariate feature trajectories for
this subgroup. These two views of C are used in the loss term L and the regularization
termR, respectively.
Our goal is to simultaneously find the multivariate longitudinal patterns for all sub-
groups, while fitting the time points of every subject xi according to which subgroup it
belongs to. This fitting is evaluated and optimized by adopting a least square loss objec-
tive function. Without loss of generality, we describe below the fitting scheme for the pth
feature of the multivariate pattern.
First, let us recall that the coefficients for the trajectories of the K different subgroups
are stored in the matrix Ĉp. For example, in Figure 4.1(c), there are two sets of the M
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coefficients describing the red and blue trajectories. For each subject xi, we introduce a
variable ζi ∈ {0, 1}K×1 to indicate its clustering membership to one of the K subgroups,
where ζi is a vector with all elements being zero except one, which is equal to 1. The
indicator selects the appropriate coefficients from Ĉp for subject xi, and it is shared among
all features of xi. We effectively assume that every subgroup is characterized by a single
multivariate pattern (illustrated by the blue columns shown in Figure 4.3). Let us denote
by tij the time of the jth follow-up scan of subject xi. Accordingly, we can compute the
B-spline basis at this time point as B(tij). Given the above notation, the least squares loss
for fitting the pth feature of xi to its corresponding global trajectory (as determined by ζi)
can be written as (xtijip −B(tij)Ĉpζi)2.
However, this loss emphasizes differences due to absolute value, which may reflect
inter-subject variability. Thus, in order to focus on differences in the shape of trajectories,
we introduce a subject-specific offset variable D ∈ RN×P×K . This can be understood as a
random intercept in a mixed effects model, where Dip contains K shifts for the pth feature
of subject xi. Each shift translates globally the values of the feature for all time points
of the subject, such that they best align with the corresponding global trajectory. This is
illustrated in Figure 4.1(d), where the longitudinal points of a single subject are shifted
according to two offsets toward two different global trajectories. The subject is assigned to
the global trajectory that best explains its own data (the orange curve in this case).
Summing up the least square fit loss for allN subjects, all P features, and all time points
of each subject constitutes the loss term L of our model:
L =
N∑
i=1
P∑
p=1
ni∑
j=1
(
x
tij
ip −B(tij)Ĉpζi −Dipζi
)2
.
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Figure 4.3: Illustration of the least squares fit: all features of the same subject share basis
B(ti), but have different coefficients from C that are chosen by the indicator ζi. To ease the
illustration, the offset variable D has not been included here.
To reach a more compact form of the loss function, we denote the pth feature of all time
points of xi as xip ∈ Rni . We also introduce the ni×M matrixB(ti) = [B(ti1), · · · , B(tini)]T
to represent the B-spline basis for all time points of xi. The above notation provides the
vectorized loss function, which will be used in the following sections:
L =
N∑
i=1
P∑
p=1
∥∥∥xip −B(ti)Ĉpζi −Dipζi1∥∥∥2
2
(4.2)
where 1 is an ni dimensional vector with all elements being 1. Figure 4.3 illustrates how
the tensor C is used in the spline fitting with this compact form (without D).
4.2.2 Regularization term
In order to avoid overfitting, we promote both the spatial and temporal smoothness of the
estimated B-spline coefficients through the introduction of two regularization terms in the
proposed framework.
Temporal smoothness of splines is encouraged because we expect individuals to change
gradually. Therefore, we penalize large spline coefficients for all subgroups and features
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by including the following quadratic penalty:
RT =
K∑
k=1
P∑
p=1
‖Cpk‖22 =
K∑
k=1
tr(C˜Tk C˜k), (4.3)
The second regularization takes into account the spatial covariance of imaging features.
This term effectively models the assumption that imaging features, which correspond to
spatially close brain regions, are also biologically connected, and thus they are likely to
undergo similar longitudinal change. Imposing a spatial regularization can effectively
improve the robustness of the method to noise, which might have been introduced by
preprocessing steps. Hence, in the framework, the difference of coefficients of features a
and b within the same subgroup is penalized according to their spatial distance. When
two features have small spatial distance, their B-spline coefficients are encouraged to be
similar. We use the spatial covariance matrix Σ ∈ RP×P introduced by [13], comprising
elements σab = e−dab , where dab is the Euclidean distance between the coordinates of brain
regions/features a and b. Thus, the second regularization term can be written as:
RS =
K∑
k=1
(
P−1∑
a=1
P∑
b=a+1
σab ‖Cak − Cbk‖22
)
=
K∑
k=1
tr{(Σ˜− Σ)C˜Tk C˜k}, (4.4)
where Σ˜ is a diagonal matrix with its diagonal elements calculated by Σ˜ii =
∑P
p=1 σip.
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4.2.3 Optimization
We combine the loss term and the regularization term, with balancing parameters η (be-
tween loss and regularization terms) and λ (between temporal and spatial regularization
terms), to obtain the objective function:
E =
P∑
p=1
N∑
i=1
‖xip −B(ti)Ĉpζi −Dipζi1‖22 + η
K∑
k=1
tr
{
(λI+ Σ˜− Σ)C˜Tk C˜k
}
. (4.5)
In order to estimate the offset variable D, the clustering memberships ζ and the spline
coefficients tensor C, we employ an adapted Expectation-Maximization algorithm to min-
imize the objective function (4.5). Specifically, we iterate between the following three steps
until the difference of objective values between two iterations is smaller than a tolerance
criterion.
1. O-step: The offset variables are calculated for each subject based on the splines
obtained in the previous iteration. We denote Dkip as the offset scalar for the pth
feature of subject xi with respect to the kth spline Cpk. The offset Dkip acts as an
“intercept” that is optimized to yield the minimal residual of the fit. Hence, it is
computed as the average of the sum of residuals when fitting the B-spline with
coefficient Cpk:
Dkip =
1
ni
1T (xip −B(ti)Cpk) . (4.6)
2. E-step: The E-step is the clustering phase of the optimization. Given the global
trajectories estimated in the previous step, and the offset variables calculated in the
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O-step, we assign each subject to the subgroup k that provides the best fit:
ζi = argmin
ζj

P∑
p=1
‖xip −B(ti)Ĉpζj −Dipζj1‖22
 . (4.7)
3. M-step: Because the loss term L and the regularization term R use two different
views of the coefficient tensor C, it is particularly difficult to derive an analytical
solution for C. Therefore, we adopted gradient descent method to estimate the
coefficients. The two cross sections, Ĉ and C˜, share columns, thus allowing the op-
timization to be achieved in a column wise fashion. Let us denote by ek ∈ {0, 1}1×K ,
a K dimensional vector with only the kth element being 1, and by p ∈ {0, 1}1×P , a
P dimensional vector with only the pth element being 1. Thus Ĉp can be rewritten
as: Ĉp =
∑K
k=1Cpkek while C˜k can be written as C˜k =
∑P
p=1Cpkp. Each column
Cpk can then be found using a quasi-Newton gradient descent method, where the
partial derivative is derived as:
∂E
∂Cpk
= −
N∑
i=1
2ekζiB(ti)
T (xip −B(ti)Ĉpζi −Dipζi1) + 2ηC˜k(λI+ Σ˜− Σ)Tp .
(4.8)
Initializing C randomly may lead to a slow convergence of this optimization process.
In order to overcome this, we randomly partition the data samples into K subgroups and
initialize each C˜k using one of the random subgroups. The clustering is performed multi-
ple times with different initializations, and we report the clustering result that yields the
lowest objective.
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4.3 Experiments
In this section, we present two sets of experiments. In the first sets of experiments, we
evaluated our approach using simulated data. We examined the capability of HELIOS to
cluster heterogeneous data by varying 1) the average length of individual trajectories, and
2) the signal to noise ratio. Lastly, we quantitatively compared the proposed approach
with two baseline curve clustering methods using the synthetic data. In the second set
of experiments, we applied HELIOS on a longitudinal study comprising cognitively nor-
mal elderly individuals to analyze the heterogeneity in aging. Our analysis revealed two
stable/reproducible subtypes, which follow distinct imaging trajectories, and also have
different cognitive profiles. Detailed investigations that are outside the scope of this paper
will be carried out in the future for elucidating all the medical implications of this finding.
4.3.1 Synthetic data
We validated our approach on a series of simulated datasets modeling heterogeneous tra-
jectories. Three independent trajectories were simulated as shown in Figure 4.4(A): 1) a
slow decreasing pattern; 2) a late fast decreasing pattern; and 3) an early fast decreasing
pattern. Time was normalized to range [0,1]. For every simulation conducted, we gener-
ated 400 samples, with 100 samples for each subgroup. Every sample has five features, and
each feature follows one of the three trajectory patterns as indicated by the color in Figure
4.4(B). Random shifts (uniformly distributed) of feature values were also introduced for
each individual trajectory.
In order to demonstrate the strength of our proposed method, we compared its perfor-
mance against two variants of k-means clustering [97]. The first variant, referred to here-
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(A) (B)
Figure 4.4: (A) The three simulated trajectory patterns. (B) Construction of four subgroups
following different multivariate patterns, where each subject has five features. The color
of each feature indicates the trajectory it follows.
after as Linear-KM, conducts linear regression separately on each feature trajectory of a
sample, and uses the estimated slopes to form a 5-dimensional clustering feature. The sec-
ond variant, termed hereafter Nonlinear-KM, aims to take into account the non-linearity
of the trajectories by first removing the mean of each feature trajectory, and then fitting the
trajectory with a regularized cubic B-spline. The estimated coefficients of all splines for one
sample are concatenated in a 20-dimensional clustering feature. Lastly, k-means clustering
is performed using the derived features to generate memberships for all the samples.
In our first experiment, we aim to evaluate the impact of the length of individual tra-
jectories in estimating the global trajectories and clustering the population. Global trajec-
tories, which span the entire time range of the longitudinal study, are estimated by taking
into account information from all subjects. However, each subject may only contribute to
the segment of the trajectory that corresponds to the period during which it was scanned.
Given that the longitudinal studies often recruit participants at different time points, while
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Figure 4.5: Comparison between the proposed method and the two k-means variants on
simulated data. The performance is quantified by the adjusted rand index, where results
are obtained by varying the lengths of individual trajectories.
also different numbers of serial scans are obtained for each participant, it is important to
understand how the length of the follow-up for each participant affects the performance
of the algorithm. This information will help us determine whether our model can success-
fully parse the heterogeneity within specific datasets.
Toward this end, we simulated individual trajectory lengths ranging from 100% to 20%
of the global trajectory. For each length setting, we drew samples with a random starting
time point and a fixed length of trajectory. These were afterward clustered using our pro-
posed method, as well as the two baseline methods. The performance of the clustering
result was evaluated by measuring the agreement between the obtained memberships and
the true memberships using the Adjusted Rand Index (ARI) [68]. We repeated this process
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Figure 4.6: Comparison between the proposed method and the two k-means variants on
simulated data. The performance is quantified by the adjusted rand index, where results
are obtained for different signal to noise ration levels, while fixing the individual trajecto-
ries length to be equal to 70% of the time range.
100 times to estimate the distribution of the performance shown in Figure 4.5. The figure
shows that all the methods could perform perfectly when each individual trajectory had
full length. However, the performance started decreasing for shorter follow-up durations.
Specifically, Linear-KM was the first to drop accuracy for individual lengths equal to 90%
of the global trajectory. Nonlinear-KM followed next for individual trajectories covering
70% of the full time range. The proposed approach was the most robust one, dropping
performance when individual trajectories were equal to half the global trajectory. Impor-
tantly, HELIOS produced reasonable clustering results even when the length of individual
trajectories was at 20% of the global trajectory.
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Secondly, we analyzed the influence of noise in disentangling heterogeneous trajectory
patterns. To evaluate the effect of noise, we fixed the length of individual trajectories to
be equal to 70% of the range of the simulation study, which is the point when we first ob-
served discrepancies between the three approaches in the previous experiment. Then, we
introduced Gaussian noise N (0, τ2) to all the features by varying the signal to noise ratio
r (defined as r = σ2/τ2) from 100 to 0.1. We repeated the simulation for each noise level
setting 100 times. The results are reported in Figure 4.6. The results demonstrate the im-
proved robustness of the proposed method compared to the k-means variants, and suggest
that a signal to noise ratio equal to 1.0 is sufficient for obtaining a reasonable clustering.
The above experiments clearly demonstrated that our proposed approach outperforms
the baseline methods by a large margin. This encouraged us to apply HELIOS to a large
longitudinal study of aging.
4.3.2 Longitudinal aging data
The Baltimore Longitudinal Study on Aging (BLSA) [140] is America’s longest-running
scientific study of human aging conducted by the National Institute on Aging (NIA). It
comprises healthy elderly adults that are followed annually with rich radiologic exami-
nations, including structural and functional MR images. Imaging data are complemented
with neuropsychological tests aiming to evaluate participants in different cognitive do-
mains. Specifically, verbal memory is assessed using the California Verbal Learning Test
(CVLT) and visual memory with the Benton Visual Retention Test (BVRT); category flu-
ency (FLUCat) and letter fluency (FLULet) assess executive function, while the card rota-
tions test (CRDRot) assesses visuospatial function. More details about the cognitive tests
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Figure 4.7: Distribution of scans per person by sex across the study age span. Each point
denotes a scan; horizontal lines connect scans from the same individual. Red, female; blue,
male.
can be found in Appendix C, while more details about the study can be found in Chapter
1.
We applied our approach to a subset of BLSA dataset, consisting of 102 subjects who
have been followed for more than six years. This subset contains 895 T1 structural MR
imaging scans in total. We present in Figure 4.7 basic demographic information (i.e., age,
gender, as well as the number of time points) for the subjects used in this study. The aver-
age follow-up time is more than 25% of the entire age range of the study, which, according
to our simulations, provides enough information for our method to delineate heteroge-
neous aging patterns within this population.
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All the brain images were skull-stripped and segmented into 34 anatomical regions of
interest (ROI), using a previously described multi-atlas segmentation protocol [38]. The
dictionary of the employed ROIs is presented in Appendix B.2. In this experiment, we
chose relatively large ROIs in order to reduce the noise level, which may be introduced
during image acquisition and preprocessing. We normalized each ROI volume by the total
intracranial volume (ICV) of the baseline visit scan. Moreover, each ROI was standardized
to a normal distribution N (0, 1) across the entire population. The individual trajectories
were smoothed afterward using a regularized cubic spline in order to further reduce noise
in the temporal dimension. A spatial covariance matrix was computed by calculating the
Euclidean distance between all pairs of ROIs in the MNI coordinate system.
The model parameters (i.e., the number of subgroups K, the regularization coefficient
η, and the balancing weight for the two regularization terms λ) were selected by evaluat-
ing the clustering results in terms of their reproducibility across multiple runs, and their
quality as quantified by the Dunn Index (DI).
In our analysis, we favor solutions exhibiting higher reproducibility as we assume that,
as one gets closer to the intrinsic dimension of the solution subspace, the clustering algo-
rithm should obtain similar results across different runs. The clustering reproducibility
was measured as follows. For each combination of model parameters, our method was
applied to the dataset for determining the optimal trajectories, as well as the clustering la-
bels for all the subjects. This procedure was repeated 100 times for each model parameter
set, and thus 100 different clustering labels were generated. The clustering reproducibility
was finally measured by computing the ARI for each pair of clusterings. The average ARI
value across all pairs was used to summarize the performance for each repetition.
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(B)
Figure 4.8: Clustering performance measured by (A) the Adjusted rand index, and (B) the
Dunn index, for different sets of hyperparameters K and η.
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Additionally, we favor solutions comprising clusters that are compact, and at the same
time, well separated. As a consequence, we prefer parameter sets that lead to higher Dunn
Index. The Dunn index was calculated as the ratio between the 5th percentile of the inter-
cluster distance and the 95th percentile of the intra-cluster distance, thus larger DI indi-
cates a better clustering. In our analysis, we adapted the calculation of the Dunn Index to
take into account the 5th percentile and 95th percentile instead of the respective minimum
and maximum values to reduce the sensitivity of the ratio to outliers, and thus improve its
stability. The intra-cluster distance measure was defined to be the sum of squared residu-
als (SSR) estimated by fitting each global trajectory to the time points of individuals that
have been assigned to it. The inter-cluster distance was calculated by estimating the SSR
by fitting global trajectories to the time points of individuals that have been assigned to
different global trajectories.
In this experiment, we set λ to be 1 in order to provide the same level of regularization
for both the spatial and temporal dimensions of the model. The following combinations of
model parameters were considered: K = {2, 3, 4} and η = {0.1, 0.05, 0.02, 0.01, 0.005, 0.002,
0.001}. The median value of the average ARI was calculated across all iterations for each
model parameter set and is shown in Figure 4.8(A). The median value of the DI results
for each parameter combination is shown in Figure 4.8(B). By taking into account the two
criteria, we chose K = 2 and η = 0.01, which yielded two subgroups consisting of 29 and
73 subjects, respectively.
Individual trajectories for all participants, as well as the global population trajectories
which were estimated by the proposed method, are shown in Figure 4.9. The two subgroup
trajectories are colored red (G1) and blue (G2), respectively. We selected six ROIs from the
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Figure 4.9: Estimated trajectories for six different ROIs. The two identified subgroups are
colored red (N=29) and blue (N=73), respectively. Subgroup trajectories are thick, while
the trajectories for each participant are thin.
right hemisphere to illustrate the longitudinal aging patterns. In order to quantify the
differences of the trajectories between the two subgroups, we defined a distance statistic
as the median of the absolute difference between the two trajectories. To estimate the
null distribution of the statistic, we proposed a nonparametric permutation test. In each
permutation, we first partitioned the entire dataset into two random groups, and then
fitted the individuals in each group using our approach with K = 1 and η = 0.01 to
derive the null hypothesis (i.e., a random fit for two global trajectories). Given the null
distribution estimated from 1000 permutations, we obtained the p values of the statistic
between the trajectories of G1 and G2. The ROIs for which the differences between the
two groups were statistically significant (False discovery rate (FDR) corrected p< 0.01) are
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Figure 4.10: The brain regions that follow statistically significant (FDR corrected p value
< 0.01) different trajectories between the two estimated subgroups found are shown. Red
indicates G1 has a faster shrinking rate than G2, while blue indicates G1 has a faster ex-
pansion rate than G2.
shown in Figure 4.10, where red indicates that G1 has a higher rate of volume decrease than
G2, and blue indicates the opposite. This nonparametric test shows that G1 is characterized
by a significantly faster volume decrease than G2 in the temporal grey matter as well as
in subcortical structures such as amygdala and hippocampus. At the same time, G1 is
characterized by a faster ventricular expansion than G2.
To further analyze the difference between the two identified subgroups, we compared
cognitive performance across clusters. Associations between cluster membership and cog-
nitive change over time were examined using linear mixed effect models (R version 3.3.2
[122]). Age, sex, subgroup, interaction between age and sex, as well as interaction between
age and subgroup, were included as fixed covariates. Random effects included intercept,
age, and subject ID. The Table 4.1 summarizes the regression results. Significant associa-
tions between subgroups and cognitive change were found for the three California Verbal
Learning Tasks (CVLtca, CVLfrs and CVLfrl) [33] and FLUCat [3]. For these cognitive
tests, G1 was characterized by a faster decline than G2.
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Table 4.1: Longitudinal cognitive score difference between two subgroups
p value p value
CVLtca 0.040* CVLfrs 0.042*
CVLfrl 0.004** BVRTot 0.560
CRDRot 0.613 FLUCat <0.0001***
FLULet 0.295
4.4 Discussion and conclusion
In this chapter, we proposed a novel framework for parsing heterogeneity in longitudinal
studies by simultaneously fitting multiple multivariate imaging trajectories, and clustering
individuals. Our approach is able to delineate global trajectories using the partial informa-
tion from individuals, while modeling explicitly heterogeneity in longitudinal processes.
The trajectories are modeled as spatiotemporally regularized cubic B-splines, which allows
for the nonlinearities and avoids overfitting.
By conducting simulations under multiple conditions, we showed that HELIOS has a
high tolerance to noise, and performs reasonably well even when the length of the follow-
up is small compared to the age range of the study. When we applied HELIOS to a BLSA
data, two subgroups were found. Subgroup G1 was characteruzed by an imaging pattern
of accelerated volume loss in regions that have been associated with neurodegenerative
symptoms in aging [74, 124, 129, 147], as well as in early stage of Alzheimer’s disease
[75, 89]. Moreover, individuals part of G1 performed statistically significantly worse than
G2 in CVLT and FLUCat tests. These results complement the neuroanatomical profiles,
and are in line with previous results associating increased atrophy in temporal pole with
decreased performance in CVLT [31, 34, 96]. Taking together, these evidence suggest that
G1 is likely to be an advanced aging group, or at the prodromal stages of neurodegenera-
87
tive disease, while G2 is more likely to be a resilient aging group, which follows a normal
aging process. Additional analyses are required to investigate this hypothesis in the future,
where a longer follow up would be crucial for boosting our confidence in the results.
Though longer follow up could allow us to better discern subtle brain changes from
the confounding variability introduced by the processing, collection of longitudinal data
is expensive and time consuming, which limits the potential use of HELIOS. Nonetheless,
HELIOS is a general method that can handle any type of sequential data. Thus, it can be
readily adapted to study the temporal dynamics in other types of data, such as time series
data from resting-state functional meganetic resonance imaging (rsfMRI), where the brain
activation of a heterogeneous population could be examined and analyzed.
Some limitations should be noted despite the advantages of this novel sophisticated
method. The large number of parameters limits our current study to the level of ROIs.
Specifically, the number of parameters in the spline coefficient tensor C is in the order of
imaging features P . However, the intrinsic dimensionality of the problem is much lower.
As observed in our experiments, the corresponding regions in left and right hemisphere
exhibit similar trajectories. Thus, a promising way to address the dimensionality prob-
lem is to adopt a sparse representation of C, where we assume that there is a low rank
decomposition of C such that all the coefficient Cpk can be represented using a few bases.
This approach may reduce the number of parameters significantly, leading to a model with
lower complexity. Alternatively, this problem might be addressed by proposing an end-
to-end framework which integrates the segmentation of high dimensional images with the
characterization of heterogeneous trajectories.
Despite the aforementioned limitations, we were able to demonstrate that the proposed
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method was able to dissect heterogeneity in both simulated and real longitudinal data. As
there is an increasing number of longitudinal studies, HELIOS will become increasingly
pertinent. Importantly, as current studies continue to collect data, HELIOS would benefit
form the longer follow-ups to better estimate group trajectories and characterize the under-
lying heterogeneity. As a consequence, HELIOS can largely complement current literature
and expand our understanding of longitudinal neurobiological processes.
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Chapter 5
Summary and Future Work
5.1 Summary
The increasing evidence for heterogeneity in neurodegenerative diseases and neuropsy-
chiatric disorders underlines the need for accurate categorization of patients in relatively
homogeneous subgroup towards deepening our understanding of neurobiological mecha-
nisms and improving disease diagnosis. The aim of this dissertation is to address the prob-
lem of disentangling heterogeneity of brain processes in neuroimaging studies. Depending
on the study design, the heterogeneity can be addressed in two ways: 1) by learning the
heterogeneous disease effect via group analysis using cross-sectional datasets, and 2) by
delineating the heterogeneous (patho)physiological process that drives the differentiation
of subgroups using longitudinal datasets. For each of these settings, we proposed analyti-
cal tools, termed CHIMERA and HELIOS respectively, which elucidate underlying hetero-
geneity, as this is reflected by imaging measures. These methods leverage machine learn-
ing approaches to best exploit the rich information provided by advanced neuroimaging
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techniques, toward paving the way for precision medicine and therapeutic innovations.
In Chapter 2, we proposed CHIMERA, which is a semi-supervised clustering method.
CHIMERA models two populations (e.g. patients and controls, responders to treatment
and non-responders) as high-dimensional point distributions, and aligns them by solv-
ing a probability density estimation problem, thus accounting for inter-subject variability.
Multiple transformations are estimated to model the underlying heterogeneity. The effect
of covariates is taken explicitly into account in the matching criterion, thus reducing the
effect of confounding variations. In order to fully explore the capability of CHIMERA, we
applied it to a large Alzheimer’s disease cohorts in Chapter 3. Four distinct reproducible
subgroups with significantly different imaging signatures were delineated. We conducted
detailed analyses evaluating the differences between the four subgroups on the difference
of cognitive scores, CSF biomarkers, white matter hyperintensities load, as well as other
available demographic and clinical variables. Our findings largely complement the current
literature of heterogeneity analysis of Alzheimer’s disease.
In Chapter 4, we proposed HELIOS, which aims to tackle heterogeneity in longitudinal
designs. We expect heterogeneous neurobiological processes in neurodegenerative and
psychiatric disorders to influence patients across their life-span, leading them to exhibit
distinct longitudinal neuroanatomical trajectories. We proposed HELIOS for disentangling
this heterogeneity by simultaneously fitting non-linear global trajectories and clustering
individuals according to their multivariate trajectory patterns. HELIOS was applied to a
large longitudinal study of aging where two subgroups were found. The subgroups were
characterized by distinct imaging trajectories and significantly different performance in
cognitive tests.
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5.2 Future work
The methods described in this thesis constitute a new paradigm for data-driven analysis
of heterogeneity in neuroimaging. There are several avenues for improving and extending
these tools which are left to investigate for future work. We detail below a number of these
avenues.
1. High dimensional imaging features.
In this thesis, the number of parameters to be optimized by the proposed meth-
ods is related to the number of features used. If we denote the number of features
by n, then CHIMERA has O(n2) parameters and HELIOS has O(n) parameters. In
medical imaging analysis, the sample size is usually small compared to the number
of features, which makes it difficult to optimize for a large number of parameters.
Therefore, our analysis across the thesis was limited to using a partition of the brains
in regions of interest, which give a coarse description of brain anatomy. Leveraging
the power of high resolution MR images by exploiting the rich voxel-wise infor-
mation could refine our characterization of disease subtypes and reveal previously
unappreciated, subtle alterations in the brain structure. Toward this end, investigat-
ing sophisticated regularization strategies is a promising strategy. The `2 norm, as
well as the Frobenius norm, which are currently used, put equal emphasis on all the
parameters. As a consequence, they are quite sensitive to the number of parameters.
However, it is possible to significantly reduce the degrees of freedom of the param-
eter space by introducing some prior knowledge to the parameters, such as spatial
regularization for CHIMERA and sparse representation for HELIOS. Further im-
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provements may also be achieved by exploring kernelized similarity measures for
HELIOS, which could provide a dual form of the optimization problem, making
feasible the inference in high-dimensional settings.
2. Reducing variations in longitudinal studies.
Longitudinal studies aim to detect subtle brain changes across time. However, these
changes are often confounded by variations introduced by different imaging scan-
ning protocols or preprocessing pipelines. Toward reducing confounding varia-
tions, a number of 4D methods [159, 166] have been proposed for longitudinal anal-
ysis. These methods typically operate by regularizing the temporal variations of
tissue segmentation. However, this enforced temporal smoothness may jeopardize
the heterogeneity analysis by reducing the underlying signal of interest. To over-
come this problem, one promising approach is to propose an end-to-end frame-
work, which unifies the segmentation process and the longitudinal heterogeneity
analysis. This approach would potentially optimize for delineating heterogeneous
temporal dynamics in the population, while also regularizing the temporal smooth-
ness for each individual.
3. Estimating the statistical power of the clusters.
Our suite of tools (i.e., CHIMERA and HELIOS) allow for the heterogeneous popu-
lation to be grouped into a user-specified number of different subgroups. In order to
quantify the imaging signature of each subgroup, we conducted voxel based anal-
ysis (VBA) for comparing the patients in each subgroup with the normal controls.
A false discovery rate (FDR) correction was applied to the statistical p value maps
to determine the significance level for each voxel after accounting for the multiple
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comparisons. In our analysis, we have yet to provide the multiple comparison cor-
rection on the cluster level. In other words, by clustering the patient population, we
obtained by construction subgroups that are different from each other in terms of
imaging presentations, and we discussed these differences based on the VBA. How-
ever, the VBA results should be discussed with care given the absence of a rigorous
procedure for correcting p values in a cluster wise manner, acknowledging that dif-
ferences at a certain level may be introduced by the clustering itself. This problem
could be partially addressed by performing VBA between each patient subgroup
and the corresponding group of normal controls, i.e., healthy subjects who undergo
the same estimated pathologic transformation towards the patient distribution dur-
ing the distribution matching process. Methods that can fully uncover the statistical
power of clusters remain an open question to be investigated.
4. Applying HELIOS to time series data.
HELIOS was currently applied to longitudinal studies, where each subject often
has a follow-up interval of several months. The collection of a longitudinal dataset
is expensive and time-consuming, which limits the use of HELIOS. On the other
hand, HELIOS is a general method that can readily handle time series data, such as
the ones produced by resting-state functional magnetic resonance imaging (rsfMRI),
electroencephalogram (EEG) and magnetoencephalography (MEG). As a consequence,
HELIOS could be useful for studying the temporal dynamics of functional activa-
tion and how these vary across populations that are heterogeneous, uniquely con-
tributing to this topic of growing interest.
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Appendix A
Software
CHIMERA is an open-source software, implemented using Python 2.7. The software pack-
age is available on NITRC1. It takes a comma separated values (csv) file as input. This file
contains imaging features of the subjects, covariate information (optional), as well as group
information (i.e., whether the subject is a control or a patient). The program performs clus-
tering using multiple random initializations, and returns the most reproducible clustering
result. Out of sample subtyping can be performed using the transformation learned and
stored by the main function. A snapshot of the CHIMERA command-line is shown in
Figure A.1.
HELIOS is also available as an open-source software, implemented using Python 2.7. It
takes a csv file as input containing the subject ID, age at scan, and ROI features. It can also
take as input the spatial locations of the ROIs in order to perform the spatial regularization.
The program produces clustering memberships as well as global longitudinal trajectories.
Multiple RANSAC [45] initializations are performed, and the best fitting is reported as the
1https://www.nitrc.org/projects/cbica chimera/
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Figure A.1: Command-line interface of CHIMERA.
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Figure A.2: Command-line interface of HELIOS.
result. A snapshot of the HELIOS command-line is shown in Figure A.2.
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Appendix B
List of regions of interest
We have used different sets of multi-atlas segmentation of ROIs [37] in Chapter 3 and
Chapter 4. Each set corresponded to a different level of brain organization hierarchy. The
names of the ROIs are listed in Table B.1 and Table B.2, respectively.
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# Name # Name
1 3rd Ventricle 41 Parietal Lobe WM L
2 4th Ventricle 42 Temporal Lobe WM R
3 Accumbens Area R 43 Temporal Lobe WM L
4 Accumbens Area L 44 Fornix R
5 Amygdala R 45 Fornix L
6 Amygdala L 46 Anterior Limb Intern. Capsule R
7 Brain Stem 47 Anterior Limb Intern. Capsule L
8 Caudate R 48 Posterior Limb Intern. Capsule R
9 Caudate L 49 Posterior Limb Intern. Capsule L
10 Cerebellum Exterior R 50 Corpus Callosum
11 Cerebellum Exterior L 51 Frontal Inferior GM L
12 Cerebellum WM R 52 Frontal Insular GM L
13 Cerebellum WM L 53 Frontal Lateral GM L
14 CSF 54 Frontal Medial GM L
15 Hippocampus R 55 Frontal Opercular GM L
16 Hippocampus L 56 Limbic Cingulate GM L
17 Inf Lat Vent R 57 Limbic Medialtemporal GM L
18 Inf Lat Vent L 58 Occipital Inferior GM L
19 Lateral Ventricle R 59 Occipital Lateral GM L
20 Lateral Ventricle L 60 Occipital Medial GM L
21 Pallidum R 61 Parietal Lateral GM L
22 Pallidum L 62 Parietal Medial GM L
23 Putamen R 63 Temporal Inferior GM L
24 Putamen L 64 Temporal Lateral GM L
25 Thalamus Proper R 65 Temporal Supratemporal GM L
26 Thalamus Proper L 66 Frontal Inferior GM R
27 Ventral DC R 67 Frontal Insular GM R
28 Ventral DC L 68 Frontal Lateral GM R
29 Vessel R 69 Frontal Medial GM R
30 Vessel L 70 Frontal Opercular GM R
31 Cere. Vermal Lob. 1-5 71 Limbic Cingulate GM R
32 Cere. Vermal Lob. 6-7 72 Limbic Medialtemporal GM R
33 Cere. Vermal Lob. 8-10 73 Occipital Inferior GM R
34 Basal Forebrain L 74 Occipital Lateral GM R
35 Basal Forebrain R 75 Occipital Medial GM R
36 Frontal Lobe WM R 76 Parietal Lateral GM R
37 Frontal Lobe WM L 77 Parietal Medial GM R
38 Occipital Lobe WM R 78 Temporal Inferior GM R
39 Occipital Lobe WM L 79 Temporal Lateral GM R
40 Parietal Lobe WM R 80 Temporal Supratemporal GM R
GM: gray matter; WM: white matter; R: right; L: left.
Table B.1: Names of 80 ROIs used in Chapter 3.
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# Name # Name
1 Basal Ganglia L 18 Limbic GM R
2 Deep GM L 19 Occipital GM R
3 Deep WM L 20 Occipital WM R
4 Frontal GM L 21 Parietal GM R
5 Frontal WM L 22 Parietal WM R
6 Limbic GM L 23 Temporal GM R
7 Occipital GM L 24 Temporal WM R
8 Occipital WM L 25 Amygdala R
9 Parietal GM L 26 Amygdala L
10 Parietal WM L 27 Hippocampus R
11 Temporal GM L 28 Hippocampus L
12 Temporal WM L 29 Basal Forebrain R
13 Basal Ganglia R 30 Basal Forebrain L
14 Deep GM R 31 Cerebellum R
15 Deep WM R 32 Cerebellum L
16 Frontal GM R 33 Ventricle R
17 Frontal WM R 34 Ventricle L
GM: gray matter; WM: white matter; R: right; L: left.
Table B.2: Names of 34 ROIs used in Chapter 4.
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Appendix C
BLSA cognitive data
The BLSA cognitive data we have used in Chapter 4 are listed below:
1. California Verbal Learning Task: 1) total of 4 list A trials (CVLtca), 2) short delay
free recall (CVLfrs), and 3) long delay free recall (CVLfrl) are used to assess verbal
learning and memory. Higher values indicate better cognitive performance.
2. Benton Visual Retention Test (BVRTot) quantifies figural memory and visuo con-
structional ability. Lower values indicate better cognitive performance.
3. CARD Rotation Test (CRDRot) measures the ability to mentally manipulate figures.
Higher values indicate better cognitive performance.
4. Category Fluency (FLUCat) measures semantic fluency. Higher values indicate bet-
ter cognitive performance.
5. Letter Fluency (FLULet) measures phonemic fluency. Higher values indicate better
cognitive performance.
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